Document:

EX-10.7

 Exhibit 10.7 
  

 
 FORM OF 

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

dated as of [            ], 2015 

by and among 
 GODADDY,
INC., 
 DESERT NEWCO, LLC, 

and each of the other parties signatory hereto 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	SECTION 1.	 	 Definitions
	  	 	2	  
			
	SECTION 2.	 	 Demand Registration
	  	 	6	  
			
	SECTION 3.	 	 Company Registration
	  	 	11	  
			
	SECTION 4.	 	 Holdback Agreement
	  	 	13	  
			
	SECTION 5.	 	 Registration Procedures
	  	 	14	  
			
	SECTION 6.	 	 Offering Procedures
	  	 	18	  
			
	SECTION 7.	 	 Expenses
	  	 	19	  
			
	SECTION 8.	 	 Exchange Registration
	  	 	19	  
			
	SECTION 9.	 	 Indemnification
	  	 	21	  
			
	SECTION 10.	 	 Underwritten Offerings
	  	 	24	  
			
	SECTION 11.	 	 Information by Eligible Holders
	  	 	24	  
			
	SECTION 12.	 	 Delay of Registration
	  	 	24	  
			
	SECTION 13.	 	 Exchange Act Compliance
	  	 	24	  
			
	SECTION 14.	 	 Termination of Registration Rights
	  	 	25	  
			
	SECTION 15.	 	 Successors and Assigns; Third Party Beneficiaries
	  	 	25	  
			
	SECTION 16.	 	 Assignment
	  	 	25	  
			
	SECTION 17.	 	 Entire Agreement
	  	 	26	  
			
	SECTION 18.	 	 Notices
	  	 	26	  
			
	SECTION 19.	 	 Severability
	  	 	28	  
			
	SECTION 20.	 	 Modifications; Amendments; Waivers
	  	 	28	  
			
	SECTION 21.	 	 Counterparts
	  	 	29	  
			
	SECTION 22.	 	 Headings; Exhibits
	  	 	29	  
			
	SECTION 23.	 	 Governing Law
	  	 	29	  
			
	SECTION 24.	 	 Waiver of Jury Trial; Consent to Jurisdiction
	  	 	29	  
			
	SECTION 25.	 	 Mergers and Other Transactions Affecting Registrable Securities
	  	 	29	  

  
 -i- 

 FORM OF 

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

This AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, dated as of
[            ], 2015 (this “Agreement”), is entered into by and among (i) GoDaddy, Inc., a Delaware corporation (the “Company”), (ii) Desert
Newco, LLC, a Delaware limited liability company (“Desert Newco”), (iii) The Go Daddy Group, Inc. (“Holdings”), (iv) Desert Newco Managers, LLC (“Employee Holdco”), (v) KKR 2006 GDG
Blocker L.P. (“KKR 2006 GDG”), KKR 2006 Fund (GDG) L.P., (“KKR 2006”), OPERF Co-Investment LLC (“OPERF”), GDG Co-Invest Blocker, L.P. (“GDG Co-Invest”) and KKR Partners III, L.P.
(“KKR Partners III” and together with KKR 2006 GDG, KKR 2006, OPERF and GDG Co-Invest, “KKR”), (vi) SLP GD Investors, LLC (“SLP GD”), SLP III Kingdom Feeder I, L.P. (“SLKF I”),
Silver Lake Technology Associates III, L.P. (“SLTA III”) and Silver Lake Partners III DE (AIV IV), L.P. (“SLP III” and, together with SLP GD, SLKF I and SLP III, “Silver Lake” and, together with
KKR, the “Sponsors”), (vii) TCV VII, L.P. (“TCV VII”), TCV VII(A), L.P. (“TCV VII(A)”) and TCV Member Fund, L.P. (“TCVMF” and, together with TCV VII and TCV VII(A),
“TCV”), (viii) QCP Fund C LP and its related persons listed on Annex I hereto (collectively, “Qatalyst”), (ix) WS Investment Company, L.L.C. (2011A) (“WSGR,” and together with the
Sponsors, TCV and Qatalyst, the “Equity Investors”), and (x) the Exchange Registration Holders (as defined herein) from time to time party hereto. 

WHEREAS, Desert Newco, Holdings, and certain of the Equity Investors are parties to that certain Registration Rights Agreement, dated as of
December 16, 2011 (the “Original Registration Rights Agreement”), and certain of the parties hereto are parties to that certain Reorganization Agreement, dated as of
[            ], 2015 (the “Reorganization Agreement”); and 

WHEREAS, it is a condition precedent to the consummation of the transactions contemplated by the Reorganization Agreement that the Company,
Desert Newco, Holdings, Employee Holdco and the Equity Investors enter into this Agreement setting forth certain rights of the Equity Holders (as defined below) and amending and restating the Original Registration Rights Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual covenants and obligations hereinafter set forth, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, each of the parties hereto hereby agree as follows: 
 SECTION
1. Definitions. 
 (a) In addition to the terms defined elsewhere in this Agreement, as used herein, the following terms shall have
the following respective meanings. Unless the context otherwise requires, the singular shall include the plural and the masculine gender shall include the feminine and neuter, and vice versa, and the word “or” shall be inclusive. 

“Affiliate” means, when used with reference to any specified Person, any other Person that directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common control with such specified Person; provided that none of the Company nor any of its Subsidiaries shall be deemed an Affiliate of any Equity Holder. 

  
 - 2 - 

 “Board” means the Board of Directors of the Company or any equivalent governing
board. 
 “Common Stock” means the Class A common stock of the Company (or any successor of the Company by combination
of shares, recapitalization, merger, consolidation, or other reorganization) and any stock into which any such Class A common stock shall have been changed or any stock resulting from any reclassification of any such Class A common stock.

 “Eligible Holders” means the Equity Holders and holders of Other Shares. 

“Eligible Shares” means the Registrable Shares and the Other Shares. 

“Equity Holders” means (i) Holdings and (ii) the Equity Investors, and (iii) any Affiliate of Holdings, the
Equity Investors or any third party, in each case to whom Holdings or any Equity Investor has assigned its rights under this Agreement in accordance with Section 16; provided that a Person shall cease to be an Equity Holder at the
time such Person ceases to hold Registrable Shares. 
 “Equity Holders’ Counsel” means the counsel selected to
represent the Equity Holders in any registration and/or offering pursuant to this Agreement by (i) the Requesting Equity Holders in the case of a Demand Registration and any offering effected pursuant to Section 2(c), (ii) the
Initiating Equity Holders in the case of a Takedown Demand or (iii) the Equity Holders (other than WSGR and Qatalyst) holding a majority of Registrable Shares being registered and/or sold (as applicable) in any other registration and/or
offering, provided that the other Equity Holders participating in any registration and/or offering may select a separate counsel to represent them in connection with such registration and/or offering. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor federal statute, and the rules and
regulations of the SEC promulgated thereunder, all as the same shall be in effect from time to time. 
 “Exchange Registration
Holders” means (i) the members of Employee Holdco and the members of Desert Newco (other than Employee Holdco, Equity Holders, Pubco and any subsidiary of Pubco) as of immediately prior to the consummation of the IPO, and any Affiliate
of any such member or any third party to whom any such member has assigned its rights under this Agreement in accordance with Section 16 and (ii) Employee Holdco for so long as Employee Holdco holds Paired Interests. 

“Executive Committee” means the Executive Committee of the Company or, if such committee does not exist, the Board or another
duly authorized committee of the Board. 
 “Group” means, with respect to any party hereto that is an Eligible Holder,
(i) such party, (ii) any Affiliate of any such party or its Affiliates, in each case to whom such party or any of its Affiliates has assigned its rights under this Agreement in accordance with Section 16; provided that a
Person shall cease to be a member of a Group (without affecting the status of any other members of such Group) at the time such Person ceases to hold Registrable Shares. 

  
 - 3 - 

 “IPO” means the first firm commitment underwritten public offering and
sale of equity securities of the Company for cash pursuant to an effective registration statement (other than on Form S-4, S-8 or a comparable form). 

“LLC Agreement” means the Second Amended and Restated Limited Liability Agreement of Desert Newco, dated as of the
date hereof (as amended and in effect from time to time). 
 “Marketed Underwritten Takedown Offering” means an
Underwritten Takedown Offering involving a customary “road show” (including an “electronic road show”) or other substantial marketing effort by the underwriters over a period of at least 48 consecutive hours. 

“Organizational Documents” means the Amended and Restated Certificate of Incorporation and the Amended and Restated
By-laws of the Company (each as amended and in effect from time to time). 
 “Other Shares” means, at any
time, those shares of Common Stock which do not constitute Primary Shares or Registrable Shares and as to which the Company has a contractual obligation, approved by the Executive Committee, to include such shares in a registration statement under
the Securities Act pursuant to the provisions of this Agreement applicable to Other Shares. 
 “Overnight Underwritten
Takedown Offering” means an Underwritten Takedown Offering other than a Marketed Underwritten Takedown Offering. 

“Paired Interest” has the meaning set forth in the LLC Agreement. 

“Person” means an individual, a corporation, a partnership, a limited liability company, a trust, an incorporated or
unincorporated association, a joint venture, a joint stock company or any other entity or body. 
 “Primary
Shares” means at any time the authorized but unissued shares of Common Stock and shares of Common Stock held by the Company in its treasury. 

“Registrable Shares” means (i) shares of Common Stock held by any member of the Equity Investor Group or the Holdings
Group (now owned or hereafter acquired) including any Common Stock issued or issuable upon conversion or exchange of other securities of the Company or its subsidiaries (including, for the avoidance of doubt, any shares of Common Stock issuable upon
exchange of Paired Interests) and (ii) any equity securities of the Company issued or issuable with respect to the securities referred to in clause (i) above by way of dividend, distribution, split or combination of securities, or any
recapitalization, merger, consolidation or other reorganization; provided, however, that any particular Registrable Shares shall cease to be Registrable Shares when (x) they have been registered for sale under the Securities Act,
the registration statement in connection therewith has been declared effective and they have been 

  
 - 4 - 

 
disposed of pursuant to such effective registration statement, (y) they have been sold in compliance with Rule 144 following the consummation of the IPO or (z) following the Restricted
Period, they are able to be sold under Rule 144 of the Securities Act (or any successor rule) in any and all three-month periods without volume limitations or other restrictions, provided that this clause (z) will not cause shares of Common
Stock held by the KKR Group, the Silver Lake Group or the TCV Group to cease to be Registrable Shares for so long as any other member of the KKR Group, the Silver Lake Group or the TCV Group, respectively, continues to hold Registrable Shares. 

“Restricted Period” has the meaning set forth in the LLC Agreement. 

“Rule 144” means Rule 144 promulgated under the Securities Act or any successor rule thereto. 

“Rule 145” means Rule 145 promulgated under the Securities Act or any successor rule thereto. 

“Rule 415” means Rule 415 promulgated under the Securities Act or any successor rule thereto. 

“SEC” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 “Shelf Participant” means any Eligible Holder listed as a potential selling shareholder on a Form S-3 in connection with
a Shelf Registration or any Eligible Holder that could be added to such Shelf Registration without the need for a post-effective amendment thereto or added by means of an automatic post-effective amendment thereto. 

“Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and
regulations of the SEC thereunder, all as the same shall be in effect from time to time. 
 “Transfer” has the meaning set
forth in the LLC Agreement. 
 “Underwritten Offering” means an offering of Common Stock or other equity securities of the
Company in which such securities are sold to an underwriter or underwriters on a firm commitment basis for reoffering to the public. 

“Underwritten Takedown Offering” means an Underwritten Offering pursuant to a Takedown Demand. 

“Units” has the meaning set forth in the LLC Agreement. 

“WKSI” means a well-known seasoned issuer, as defined in the Rule 405 of the Securities Act. 

  
 - 5 - 

 (b) For all purposes of and under this Agreement, the following capitalized terms shall have the
respective meanings ascribed to them on the page of this Agreement set forth opposite each such capitalized term below: 

 

					
	Affiliate	  	 	3	  
	Agreement	  	 	2	  
	Assignee	  	 	26	  
	Board	  	 	3	  
	Common Stock	  	 	3	  
	Company	  	 	2	  
	Demand Registration	  	 	7	  
	Desert Newco	  	 	2	  
	Eligible Holders	  	 	3	  
	Eligible Shares	  	 	3	  
	Equity Holders	  	 	3	  
	Equity Holders’ Counsel	  	 	3	  
	Equity Investors	  	 	2	  
	Exchange Act	  	 	3	  
	Exchange Registration	  	 	20	  
	Exchange Registration Statement	  	 	20	  
	Executive Committee	  	 	3	  
	FINRA	  	 	16	  
	Form S-3	  	 	7	  
	GDG Co-Invest	  	 	2	  
	Group	  	 	4	  
	Holdback Period	  	 	13	  
	Holdings	  	 	2	  
	Initiating Equity Holder	  	 	10	  
	IPO	  	 	4	  
	KKR	  	 	2	  
	KKR 2006	  	 	2	  
	KKR 2006 GDG	  	 	2	  
	KKR Partners III	  	 	2	  
	LLC Agreement	  	 	4	  
	Marketed Underwritten Takedown Offering	  	 	4	  
	OPERF	  	 	2	  
	Organizational Documents	  	 	4	  
	Original Registration Rights Agreement	  	 	2	  
	Other Shares	  	 	4	  

					
	Overnight Underwritten Takedown Offering	  	 	4	  
	Paired Interest	  	 	4	  
	Person	  	 	4	  
	Primary Shares	  	 	4	  
	Qatalyst	  	 	2	  
	Registrable Shares	  	 	4	  
	Registration Expenses	  	 	19	  
	Reorganization Agreement	  	 	2	  
	Requesting Equity Holders	  	 	7	  
	Restricted Period	  	 	5	  
	Rights Termination Date	  	 	25	  
	Rule 144	  	 	5	  
	Rule 145	  	 	5	  
	Rule 415	  	 	5	  
	SEC	  	 	5	  
	Securities Act	  	 	5	  
	Shelf Participant	  	 	5	  
	Shelf Registration	  	 	9	  
	Silver Lake	  	 	2	  
	SLKF I	  	 	2	  
	SLP GD	  	 	2	  
	SLP III	  	 	2	  
	SLTA III	  	 	2	  
	Sponsors	  	 	2	  
	Takedown Demand	  	 	10	  
	TCV	  	 	2	  
	TCV VII	  	 	2	  
	TCV VII(A)	  	 	2	  
	TCVMF	  	 	2	  
	Transfer	  	 	5	  
	Underwritten Offering	  	 	5	  
	Underwritten Takedown Offering	  	 	5	  
	Units	  	 	5	  
	WKSI	  	 	6	  
	WSGR	  	 	2	  

 
 

  
 SECTION 2. Demand
Registration. 
 (a) If the Company shall receive from any member of the Sponsor Group or from any member of the Holdings Group, in each
case holding Registrable Shares (the “Requesting Equity Holders”) a written request that the Company effect a registration with 

  
 - 6 - 

 
respect to all or a part of the Registrable Shares held by the Requesting Equity Holders (a “Demand Registration”), then, unless the Requesting Equity Holders have failed to
receive any consent to Transfer such Registrable Shares required under the LLC Agreement or the Stockholder Agreement (as defined in the LLC Agreement), as applicable, the Company will: 

(i) within ten (10) days after the date of such request, give written notice of the proposed registration to all Equity
Holders (other than the Requesting Equity Holders) and the holders of Other Shares; and 
 (ii) use its reasonable best
efforts to, as soon as practicable and in any event within ninety (90) days, in the case of any registration of shares conducted on a registration statement on Form S-1 under the Securities Act (or any comparable or successor form or forms
thereto) or within forty-five (45) days, in the case of a registration of shares conducted on a registration statement on Form S-3 under the Securities Act (or any comparable or successor form or forms thereto, a “Form S-3”),
effect such registration (which shall, in the case of a secondary offering, be on Form S-3 if the Company is qualified for registration on Form S-3 at such time) (including, without limitation, the execution of an undertaking to file post-effective
amendments, appropriate qualifications under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act) as may be so requested and as would permit or facilitate the sale
and distribution of all of such Registrable Shares as are specified in such request, together with all or such portion of (A) the other Registrable Shares joining in such request as are specified in a written request from any Equity Holder
received by the Company, (B) any Other Shares entitled to participate therein as are specified in a written request from the holders of such Other Shares received by the Company, and/or (C) any Primary Shares proposed to be included in
such registration by the Company by notice from the Company to the Requesting Equity Holders, in each case within twenty (20) days after written notice from the Company is given under Section 2(a)(i) above; provided that the
Company shall not be obligated to effect, or take any action to effect, any such registration pursuant to this Section 2(a): 

(1) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such
registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act or applicable rules or regulations thereunder; 

(2) With respect to any particular Requesting Equity Holder, if all the Registrable Shares proposed to be registered by such Requesting Equity
Holder and its Group pursuant to this Section 2(a) could be sold within ninety (90) days pursuant to Rule 144 or Rule 145; 

(3) If the Company shall furnish to the Requesting Equity Holders a certificate signed by the Chief Executive Officer (or other authorized
officer) of the Company stating that in the good faith judgment of the 

  
 - 7 - 

 
Executive Committee it would be detrimental to the Company or its stockholders for a registration statement to be filed in the near future, in which case the Company’s obligation to use its
reasonable best efforts to comply with this Section 2(a), and its related obligations under Section 5, shall be deferred for a period not to exceed ninety (90) days from the date of receipt of written request from the
Requesting Equity Holders (provided that the Company shall only be permitted one deferral pursuant to this Section 2(a)(ii)(3) or Section 2(b) in any twelve-month period) and each Eligible Holder shall keep
confidential the fact that such a deferral is in effect, as well as the certificate referred to above and its contents, unless and until otherwise notified by the Company, except (A) for disclosure to such Eligible Holder’s employees,
officers, directors, agents, legal counsel, accountants, auditors and other professional representatives and advisers who reasonably need to know such information solely for purposes of assisting the Eligible Holder with respect to its investment in
Common Stock or Units and agree to keep it confidential, (B) for disclosures to the extent required in order to comply with reporting obligations to its limited partners or other direct or indirect investors who have agreed to keep such
information confidential, (C) if and to the extent such matters are publicly disclosed by the Company or any of its subsidiaries or any other Person (except to the extent that such other Person learned of such confidential information as a
result of disclosure by the Eligible Holder in violation of this Agreement) that, to the knowledge of such Eligible Holder after inquiry, was not subject to a similar obligation or duty of confidentiality to the Company and its subsidiaries and
(D) as required by law, rule or regulation (provided that the Eligible Holder gives prompt notice of such use in writing, to the extent permitted by law, rule or regulation, and reasonably cooperates with the Company should the Company,
at the Company’s sole expense, desire to seek a protective order or other appropriate remedy to protect the confidentiality of such confidential information prior to disclosure); or 

(4) If the Requesting Equity Holders propose to register Registrable Shares at an expected offering price of less than $50,000,000 (net of
Registration Expenses) in the aggregate; provided that this clause (4) shall not apply to a Shelf Registration covering an unspecified number of shares in accordance with Section 2(b). 

Subject to the provisions of Section 2(c) below, the Company may, in its sole discretion, include Other Shares in the registration statement filed
pursuant to the request of the Requesting Equity Holders pursuant to this Section 2(a). 
 (b) Shelf Registration. At any
time and from time to time when the Company is eligible to utilize Form S-3 to sell shares in a secondary offering on a delayed or continuous basis in accordance with Rule 415 (a “Shelf Registration”), any demand made pursuant to
Section 2(a) may, at the option of the Requesting Equity Holders, be a demand for a Shelf 

  
 - 8 - 

 
Registration; provided that no more than two demands for Shelf Registration may be made in any 12 month period by any member of the KKR Group, the Silver Lake Group or the Holdings Group,
respectively. For the avoidance of doubt, the rights of Eligible Holders to receive notice of any Demand Registration and to include Eligible Shares in any such Demand Registration pursuant to Section 2(a) hereof shall apply in
connection with any such Shelf Registration. If at the time of such request the Company is a WKSI, (x) if the Company so elects, such Shelf Registration may also cover an unspecified number of shares to be sold by the Company, and (y) if
the Requesting Equity Holders so elect, such Shelf Registration may cover an unspecified number of shares to be sold by the Equity Holders. The Company may suspend the use of any effective Shelf Registration by written notice to the holders of
Registrable Shares listed as potential selling shareholders therein under the circumstances, for the period and subject to the limitations set forth in Section 2(a)(ii)(3). 

(c) Underwriting. In the case of any offering made in accordance with Section 2(a), other than an offering made pursuant to
a Takedown Demand: 
 (i) if the Requesting Equity Holders intend to distribute the Registrable Shares by means of an
Underwritten Offering, they shall so advise the Company as a part of its request made pursuant to Section 2(a) and the managing underwriter for such Underwritten Offering shall be chosen by the holders of a majority in aggregate amount
of the Registrable Shares (x) being registered by members of the Sponsor Group, in the case of an offering pursuant to a Demand Registration where any member of the Sponsor Group is the Requesting Equity Holder or (y) in any other case,
being registered by all Equity Holders, and in each case, with the consent of the Company, which consent shall not be unreasonably withheld, delayed or conditioned. If the holders of Other Shares request inclusion of such shares, the Equity Holders
agree that the Company may include such shares in the Underwritten Offering so long as such holders agree to be bound by the applicable provisions of this Section 2. The Requesting Equity Holders and the Company shall (together with all
other Eligible Holders proposing to distribute their Eligible Shares through such Underwritten Offering) enter into an underwriting agreement in customary form and reasonably acceptable to the Company with the underwriter or underwriters.
Notwithstanding any other provision of this Section 2, if the managing underwriter selected as provided in this Section 2(c) determines that marketing factors require a limitation on the number of shares to be underwritten in
such Underwritten Offering, the managing underwriter may limit the number of shares proposed to be included in such registration and Underwritten Offering as follows: 

(1) first, the Primary Shares shall be excluded from such registration to the extent so required by such limitation; 

(2) second, to the extent further limitation is required by the managing underwriter, the Other Shares shall be excluded from
such registration to the extent so required by such limitation such that the number of shares to be included by such holders of Other Shares shall be determined on a pro rata basis based upon the aggregate number of Other Shares held by each such
holder seeking registration; and 

  
 - 9 - 

 (3) third, to the extent further limitation is required by the managing
underwriter, the remaining Registrable Shares held by Equity Holders shall be excluded from such registration to the extent so required by such limitation such that the number of Registrable Shares held by Equity Holders to be included in the
offering shall be determined on a pro rata basis based upon the aggregate number of Registrable Shares held by each Equity Holder seeking registration. 

(ii) No Other Shares, Primary Shares or Registrable Shares excluded from the Underwritten Offering by reason of the
underwriter’s marketing limitation shall be included in such Underwritten Offering, and any Eligible Holder who has requested inclusion in such Underwritten Offering as provided above (including the Requesting Equity Holders) may elect to
withdraw therefrom at any time prior to the effectiveness of such registration statement by written notice to the Company, the managing underwriter and the Requesting Equity Holders; provided that, if the underwriters’ counsel reasonably
determines that such withdrawal would materially delay the registration or require a recirculation of the prospectus, then no Eligible Holder shall have the right to withdraw unless the Requesting Equity Holders have elected to withdraw. 

(d) Shelf Takedowns. At any time when a Shelf Registration statement is effective and its use has not been suspended by the Company
pursuant to Section 2(b), upon the demand (a “Takedown Demand”) by any member of the KKR Group, the Silver Lake Group or the Holdings Group that is a Shelf Participant holding Registrable Shares at such time (the
“Initiating Equity Holder”), the Company will facilitate in the manner described in this Agreement a “takedown” of shares off of such Shelf Registration; provided that (i) each of the KKR Group, the Silver Lake
Group and the Holdings Group shall have the right to make no more than two Takedown Demands, in each case, in any twelve (12) month period; (ii) the Company shall not be obligated to effect a Marketed Underwritten Takedown Offering unless
the shares requested to be sold in such offering have an aggregate market value (based on the most recent closing price of the Common Stock at the time of the demand) of at least $25,000,000 (net of Registration Expenses); and (iii) the Company
will provide (x) in connection with any Overnight Underwritten Takedown Offering at least two (2) business days notice to any Equity Investor (other than the Initiating Equity Holder) that is a Shelf Participant, and (y) in connection
with any Marketed Underwritten Takedown Offering, at least five (5) business days notice to any Eligible Holder (other than the Initiating Equity Holder) that is a Shelf Participant entitled to participate therein. If any Shelf Participants
entitled to receive a notice pursuant to clause (iii) of the preceding sentence request inclusion of their Eligible Shares (by notice to the Company, which notice must be received by the Company no later than (A) in the case of an
Overnight Underwritten Takedown Offering, the business day following the date notice is given to such participant or (B) in the case of a Marketed Underwritten Takedown Offering, three (3) calendar days following the date notice is given
to such participant) the Company shall include such shares in the Underwritten Takedown Offering so long as such participants agree to be bound by the applicable provisions of this Section 2; provided that (1) the Initiating
Equity Holder shall maintain the right to select the managing underwriter for such offering (with the consent of the Company, which consent shall not be unreasonably withheld, delayed or conditioned) and (2) if such managing underwriter
determines that marketing factors require a limitation on the number of shares to be underwritten, the managing underwriter may limit the 

  
 - 10 - 

 
number of shares proposed to be included in such offering such that the number of Eligible Shares to be included shall be determined in the manner set forth in Section 2(c). The Shelf
Participants participating in such offering and the Company shall enter into an underwriting agreement in customary form with the underwriter or underwriters of such offering. Any Shelf Participant who has requested inclusion in such Underwritten
Takedown Offering as provided above (including the Initiating Equity Holder) may elect to withdraw therefrom at any time prior to the consummation of the takedown by written notice to the Company, the managing underwriter and the Initiating Equity
Holder; provided that, if the underwriters’ counsel reasonably determines that such withdrawal would require a recirculation of the prospectus, then no Eligible Holder shall have the right to withdraw unless the Initiating Equity Holder
has elected to withdraw. 
 (e) Effective Registration Statement. Should a Takedown Demand not be consummated due to the
failure of the Initiating Equity Holder to perform its obligations under this Agreement, or in the event the Initiating Equity Holder withdraws or does not pursue the offering contemplated by the Shelf Takedown request as provided for in
Section 2(d) above, then such Takedown Demand shall be deemed to have been effected for purposes of clause (i) of Section 2(d) unless such offering does not proceed because (x) a material adverse change occurred in
the condition (financial or otherwise), business, assets, properties, operations or results of operations of the Company and its subsidiaries taken as a whole subsequent to the date of the delivery of the Takedown Demand referred to in
Section 2(d) above, (y) use of the Shelf Registration was subsequently suspended by the Company as provided in Section 2(b), or (z) the Shelf Registration statement did not remain continuously effective until all
the Registrable Shares subject to such Takedown Demand were sold because (i) the Company was not in compliance in all material respects with its obligations under this Agreement, or (ii) the Shelf Registration was interfered with by any
stop order, injunction, or other order or requirement of the SEC or other governmental agency or court, in which event such Takedown Demand shall not be deemed to have been effected for purposes of clause (i) of Section 2(d). 

(f) For avoidance of doubt, this Section 2 is subject in all respects to the provisions of Article VIII of the LLC Agreement and
Section 3.9 of the Stockholder Agreement (as defined in the LLC Agreement), as applicable, and nothing in this Section 2 shall limit or otherwise modify the provisions thereof, including with respect to the limitations on Transfer
set forth therein. 
 SECTION 3. Company Registration. 

(a) If the Company shall determine to register any Primary Shares or Other Shares under the Securities Act, other than (A) in an IPO,
(B) pursuant to a registration statement on Form S-4 or S-8 (or such similar successor forms then in effect under the Securities Act), (C) pursuant to a registration relating solely to an offering and sale to employees, directors or
consultants of the Company or its subsidiaries pursuant to any employee stock plan or other benefit plan arrangement, (D) pursuant to a registration relating to a Rule 145 transaction, (E) pursuant to a registration by which the Company is
offering to exchange its own securities for other securities (including pursuant to Section 8), (F) pursuant to a registration statement relating solely to dividend reinvestment or similar plans or (G) pursuant to a
registration statement by 

  
 - 11 - 

 
which only the initial purchasers and subsequent transferees of debt securities of the Company or any of its subsidiaries that are convertible or exchangeable for Common Stock and that are
initially issued pursuant to an applicable exemption from the registration requirements of the Securities Act may resell such notes and sell the Common Stock into which such notes may be converted or exchanged, then in each case, the Company will:

 (i) promptly give to the Eligible Holders a written notice thereof (which shall include a list of the jurisdictions in
which the Company intends to attempt to qualify such securities under the applicable blue sky or other state securities laws and the number of securities intended to be disposed); and 

(ii) include in such registration (and any related qualification under blue sky laws or other compliance), and in any
underwriting involved therein, all the Eligible Shares specified in a written request or requests by any Eligible Holder (provided that such Eligible Holder has indicated within twenty (20) days after written notice from the Company
described in clause (i) above is given that such Eligible Holder desires to sell Eligible Shares in the manner of distribution proposed by the Company) except (x) as set forth in Section 3(b) below and (y) during the
Restricted Period, if no Eligible Holder that is a member of the Sponsor Group has indicated within the allotted time period that it desires to sell Registrable Shares in the manner of distribution proposed by the Company. 

(b) Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an underwriting,
the Company shall so advise the Eligible Holders as a part of the written notice given pursuant to Section 3(a)(i). In such event, the right of each Eligible Holder to registration pursuant to this Section 3(b) shall be
conditioned upon such Eligible Holder’s participation in such underwriting and the inclusion of such Eligible Holder’s Registrable Shares in the underwriting to the extent provided herein. The participating Eligible Holders shall (together
with the Company and the other stockholders distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the underwriter or underwriters participating in the underwriting. Notwithstanding any
other provision of this Section 3, if the managing underwriter determines that marketing factors require a limitation on the number of shares to be underwritten, the managing underwriter may limit the number of Eligible Shares proposed
to be included in such registration and underwriting by excluding Eligible Shares to the extent so required by such limitation such that the number of Eligible Shares to be included by each Eligible Holder shall be determined on a pro rata
basis based upon the aggregate number of Eligible Shares held by each such Eligible Holder; provided, that if the Company proposes to use proceeds from the sale of any Primary Shares to repurchase Common Stock, Units or Paired Interests from
existing securityholders, then (1) if such existing securityholders are Eligible Holders, such Primary Shares shall be treated as Eligible Shares for the purpose of this sentence, and (2) such existing securityholders are not Eligible
Holders, such Primary Shares shall excluded from the underwriting before any Eligible Shares are excluded from the underwriting. 
 Any
Eligible Holder or other stockholder may elect to withdraw from such underwriting at any time prior to the consummation of the offering by written notice to the Company and the 

  
 - 12 - 

 
underwriter. Any Eligible Shares or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration; provided that, if the underwriter’s
counsel reasonably determines that such withdrawal would materially delay the registration or require a recirculation of the prospectus, then the Eligible Holders shall have no right to withdraw. In the event that any Eligible Holder has requested
inclusion of Eligible Shares in a Shelf Registration initiated by the Company, such Eligible Holder shall have the right, but not the obligation, to participate in any offering of the Company’s equity securities under such shelf registration.

 (c) For avoidance of doubt, this Section 3 is subject in all respects to the provisions of Article VIII of the LLC Agreement
and Section 3.9 of the Stockholder Agreement (as defined in the LLC Agreement), as applicable, and nothing in this Section 2 shall limit or otherwise modify the provisions thereof, including with respect to the limitations on
Transfer set forth therein. 
 SECTION 4. Holdback Agreement. 

(a) If requested by the managing underwriters of an Underwritten Offering (including the IPO), neither the Eligible Holders nor the Company
shall offer for sale (including by short sale), grant any option for the purchase of, or otherwise transfer (whether by actual disposition or effective economic disposition due to cash settlement, derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of Common Stock or otherwise), any equity securities (or interests therein) in the Company without the prior written consent of the Company for a period designated by the
Company in writing to the Eligible Holders, which shall begin (i) in the case of the IPO, on the date the Company first files a prospectus that includes a price range in respect of the IPO, (ii) in the case of a Takedown Demand, the
earlier of the date of the underwriting agreement and the commencement of marketing efforts or (iii) for any other offering, 7 days before the effective date of the registration statement, and shall not last longer than 180 days following such
effective date for the IPO and ninety (90) days following such effective date for any offering thereafter, subject, in each case, to reasonable extension as determined by the Company to the extent necessary to avoid a blackout of research
reports under applicable regulations of FINRA (each such period, a “Holdback Period”); provided that except (x) in the case of an IPO, no Holdback Period shall apply to any Equity Holder who is not entitled to
participate in an Underwritten Offering hereunder (disregarding the effect of any underwriter cutbacks imposed on such Equity Holder) and (y) in the case of an Overnight Underwritten Takedown Offering, no Holdback Period shall apply to the TCV
Group if no member of the TCV Group is participating in such Overnight Underwritten Takedown Offering. Notwithstanding the foregoing, the Company may effect a public sale or distribution of securities of the type described above and during the
periods described above if such sale or distribution is made pursuant to Registrations on Form S-4 or S-8 or any successor form to such Forms or as part of any Registration of securities for offering and sale to employees, directors or consultants
of the Company and its Subsidiaries pursuant to any employee stock plan or other employee benefit plan arrangement. If requested by the managing underwriter of any such offering and subject to the approval of the Company, the Company and the
Eligible Holders shall execute a separate agreement to the foregoing effect. The Company and Desert Newco may impose stop-transfer instructions with respect to the Common Stock, 

  
 - 13 - 

 
Units or other securities subject to the foregoing restriction until the end of the Holdback Period. Notwithstanding the foregoing, if the managing underwriters in connection with any such
offering waive all or any portion of the Holdback Period with respect to any Eligible Holders, the Company, the Requesting Equity Holders or the Initiating Equity Holders, as applicable, will use reasonable best efforts to cause such managing
underwriters to apply the same waiver to all other Eligible Holders. The obligations of any person under this Section 4 are not in limitation of holdback or transfer restrictions that may otherwise apply by virtue of any other agreement
or undertaking. 
 SECTION 5. Registration Procedures. If and whenever the Company is under an obligation pursuant to the provisions
of this Agreement to effect the registration of any Eligible Shares, the Company shall, as expeditiously as reasonably possible: 
 (a)
prepare the required registration statement, including all exhibits and financial statements required under the Securities Act to be filed therewith, and before filing a registration statement or prospectus (including a free writing prospectus), or
any amendments or supplements thereto, furnish to the underwriters, if any, and the Equity Holders (other than WSGR and Qatalyst) participating in such offering, if any, copies of all documents prepared to be filed, which documents shall be subject
to the review of such underwriters, such Equity Holders and the Equity Holders’ Counsel; 
 (b) use its reasonable best efforts to
cause a registration statement that registers such Eligible Shares to become and remain effective for a period of 120 days (subject to any extension provided for in Section 5(c)) or until all of such Eligible Shares have been disposed of
(if earlier); provided, however, that in the case of any Shelf Registration, the 120 day period shall be extended, if necessary, to keep the registration statement effective until all such Eligible Shares are sold; 

(c) furnish, without charge, at least five (5) business days before filing a registration statement that registers such Eligible Shares,
a prospectus relating thereto or any amendments or supplements relating to such a registration statement or prospectus to the Equity Holders’ Counsel and fairly consider such reasonable changes in any such documents prior to or after the filing
thereof as such Equity Holders’ Counsel may request; 
 (d) prepare and file with the SEC such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be (i) reasonably requested by any Eligible Holder participating in such registration (to the extent such request relates to information relating to such Eligible
Holder) (ii) necessary to keep such registration statement effective for at least a period of 120 days or until all of such Eligible Shares have been disposed of (if earlier) and to comply with the provisions of the Securities Act with respect
to the sale or other disposition of such Eligible Shares; provided, however, that in the case of any Shelf Registration, such 120 day period shall be extended, if necessary, to keep the registration statement effective until all such
Eligible Shares are sold, (iii) requested by the Eligible Holders (or required in the case of a Shelf Registration unless the Company elects to suspend use of such Registration Statement pursuant to Section 2(b)), so that the
prospectus used in connection with such registration shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not

  
 - 14 - 

 
misleading in light of the circumstances then existing or (iv) requested jointly by the managing underwriter or underwriters and the Requesting Equity Holders or the Initiating Equity
Holders, as applicable, relating to the plan of distribution therein; and, with respect to a Shelf Registration, if during such period the Company ceases to be eligible to continue such Shelf Registration on the original registration statement
(whether by virtue of ceasing to be eligible to use Form S-3, by virtue of expiration of such registration statement pursuant to Rule 415(a)(5), or otherwise), the Company shall register the applicable shares on a replacement registration statement,
which shall be on Form S-3 if the Company is then eligible for such registration statement or, otherwise, on Form S-1, and shall continue such Shelf Registration, and amend and supplement such replacement registration statement from time to time, as
required by this Agreement; 
 (e) notify the Equity Holders’ Counsel and each Equity Holder (other than WSGR and Qatalyst) in writing
(i) when the applicable registration statement or any amendment thereto has been filed or becomes effective, and when any applicable prospectus or any amendment or supplement thereto has been filed, (ii) of the receipt by the Company of
any notification with respect to any comments by the SEC with respect to such registration statement or prospectus or any amendment or supplement thereto or any request by the SEC for the amending or supplementing thereof or for additional
information with respect thereto, (iii) of the receipt by the Company of any notification with respect to the issuance by the SEC of any stop order suspending the effectiveness of such registration statement or prospectus or any amendment or
supplement thereto or the initiation or threatening of any proceeding for that purpose, and (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification of such Eligible Shares for sale in any
jurisdiction or the initiation or threatening of any proceeding for such purposes; and, upon occurrence of any of the events mentioned in clauses (iii) and (iv) use its reasonable best efforts to prevent the issuance of any stop order or
obtain the withdrawal thereof as soon as possible; 
 (f) use its reasonable best efforts to register or qualify such Eligible Shares under
such other securities or blue sky laws of such jurisdictions as the Eligible Holders reasonably request and do any and all other acts and things which may be reasonably necessary or advisable to enable the Eligible Holders to consummate the
disposition in such jurisdictions of the Eligible Shares owned by the Equity Holders (other than WSGR and Qatalyst); provided, however, that the Company will not be required to qualify to do business, subject itself to taxation or
consent to general service of process in any jurisdiction, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(g) furnish to the Eligible Holders such number of copies of such registration statement and of each amendment and supplement thereto (in each
case, including all exhibits), the prospectus, if any, contained in such registration statement or other prospectus, including a preliminary prospectus or any free writing prospectus, in conformity with the requirements of the Securities Act; 

(h) without limiting Section 5(f) above, use its reasonable best efforts to cause such Eligible Shares to be registered with or
approved by such other governmental agencies or authorities as may be necessary by virtue of the business and operations of the Company to enable the Eligible Holders (to the extent the Eligible Holders then hold such Eligible Shares) to consummate
the disposition of such Eligible Shares; 

  
 - 15 - 

 (i) notify the Eligible Holders on a timely basis at any time when a prospectus relating to such
Eligible Shares is required to be delivered under the Securities Act upon discovery that, or upon the happening of any event as a result of which, the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(j) provide a transfer agent and registrar (which may be the same entity) for such Eligible Shares and a CUSIP number for such Eligible
Shares, in each case no later than the effective date of such registration statement; 
 (k) use its reasonable best efforts to cause all
such Eligible Shares registered pursuant to this Agreement to be listed on any national securities exchange or to be authorized for quotation on an automated quotation system on which any shares of the Common Stock are listed or quoted, or, if the
Common Stock is not then listed or quoted, use its reasonable best efforts to list such Eligible Shares on a national securities exchange, or to authorize them for quotation on an automated quotation system; 

(l) use its reasonable best efforts to obtain the withdrawal of any order suspending the effectiveness of the registration statement or the
use of any preliminary or final prospectus; 
 (m) reasonably cooperate with each Eligible Holder and each underwriter, and their respective
counsel in connection with any filings required to be made with the Financial Industry Regulatory Authority (“FINRA”), and any securities exchange on which such Eligible Shares are traded or will be traded; 

(n) take no direct or indirect action prohibited by Regulation M under the Exchange Act; provided, however, that to the extent
that any prohibition is applicable to the Company, the Company will take such action as is necessary to make any such prohibition inapplicable; 

(o) in the case of an offering pursuant to a registration that is not an Underwritten Offering, cooperate with the sellers of Eligible Shares
to facilitate the timely preparation and delivery of certificates, to the extent permitted by applicable law, not bearing any restrictive legends representing the Eligible Shares to be sold, and cause such Eligible Shares to be issued in such
denominations and registered in such names in accordance with the instructions of the sellers of Eligible Shares at least three (3) business days prior to any sale of Eligible Shares and instruct any transfer agent and registrar of Eligible
Shares to release any stop transfer orders in respect thereof; 
 (p) make such representations and warranties to the Eligible Holders
participating in such offering and the underwriters or agents, if any, in form, substance and scope as are customarily made by issuers in secondary Underwritten Offerings; 

  
 - 16 - 

 (q) obtain for delivery to the Eligible Holders participating in such offering and to the
underwriter or underwriters, if any, an opinion or opinions from counsel for the Company dated the effective date of the registration statement or, in the event of an Underwritten Offering, the date of the closing under the underwriting agreement,
in customary form, scope and substance, which opinions shall be reasonably satisfactory to the Equity Holders (other than WSGR and Qatalyst) or underwriters, as the case may be, and their respective counsel; 

(r) make available upon reasonable notice at reasonable times and for reasonable periods for inspection by any Equity Holder (other than WSGR
and Qatalyst), by any underwriter participating in any disposition to be effected pursuant to such registration statement and by any attorney, accountant or other agent retained by such Equity Holders (including the Equity Holders’ Counsel) or
any such underwriter in connection with such registration statement (collectively, “Representatives”), all pertinent financial and other records, pertinent corporate documents and properties of the Company, and cause all of the
Company’s officers, directors and employees and the independent public accountants who have certified its financial statements to make themselves available to discuss the business of the Company and to supply all information reasonably
requested by any such Person or its Representatives in connection with such registration statement (“collectively, “Confidential Information”) as shall be necessary to enable them to exercise their due diligence responsibility;
provided that any such Person or Representative gaining access to Confidential Information pursuant to this Section 5(r) shall agree to hold in strict confidence and shall not make any disclosure or use any Confidential
Information, unless (w) the release of such information is requested or required by law or by deposition, interrogatory, requests for information or documents by a governmental entity, subpoena or similar process (provided that such
Person shall give prompt and timely written notice prior to such release, to the extent permitted by law, and shall reasonably cooperate with the Company should the Company, at the Company’s sole expense, desire to seek a protective order prior
to disclosure), (x) such information is or becomes publicly known other than through a breach of this or any other agreement of which such Person has knowledge after inquiry, (y) such information is or becomes available to such Person on a
non-confidential basis from a source other than the Company who is not known by such Person, after inquiry, to be prohibited or restricted from disclosing such information to such Person by contractual, legal or fiduciary obligation or (z) such
information is independently developed by such Person without the use of or access to any Confidential Information, and each Person shall be responsible for any breach of the terms of this Section 5(r) by such Person or its
Representatives, and shall take all appropriate steps to safeguard Confidential Information from disclosure, misuse, espionage, loss and theft; and 

(s) provide and cause to be maintained a transfer agent and registrar for all Eligible Shares covered by the applicable registration statement
from and after a date not later than the effective date of such registration statement. 
 Each Eligible Holder, upon receipt of any notice
from the Company of any event of the kind described in Section 5(i) hereof, shall forthwith discontinue disposition of the Eligible Shares pursuant to the registration statement covering such Eligible Shares until such holder’s
receipt of the copies of the supplemented or amended prospectus contemplated by Section 5(i) hereof (provided that, in the case of a Shelf Registration, if such suspension lasts for longer than

  
 - 17 - 

 
ten (10) consecutive business days, it shall count as a suspension for purposes of the limits set forth in Section 2(a)(ii)(3)), and, if so directed by the Company, such Eligible
Holder shall destroy all copies, other than permanent file copies then in such holder’s possession, of the prospectus covering such Eligible Shares at the time of receipt of such notice. 

If the disposition by any Eligible Holder of its securities is discontinued pursuant to the foregoing sentence, the Company shall extend the
period of effectiveness of the registration statement by the number of days during the period from and including the date of the giving of such notice to and including the date when such Eligible Holder shall have received, in the case of
Section 5(e)(iv), notice from the Company that such stop order or suspension of effectiveness is no longer in effect and, in the case of Section 5(i), copies of the supplemented or amended prospectus contemplated by
Section 5(i). 
 SECTION 6. Offering Procedures. If and whenever the Company is under an obligation pursuant to the
provisions of this Agreement to facilitate (x) an Underwritten Offering pursuant to a Demand Registration or (y) an Underwritten Takedown Offering (including a Marketed Underwritten Takedown Offering), the Company shall, as expeditiously
as practicable: 
 (a) use its reasonable best efforts to obtain, and to furnish to the Eligible Holders and each underwriter, “cold
comfort” letters from its independent certified public accountants in customary form and at customary times and covering matters of the type customarily covered by cold comfort letters; 

(b) cooperate with the sellers of Eligible Shares and the managing underwriter to facilitate the timely preparation and delivery of
certificates, to the extent permitted by applicable law, not bearing any restrictive legends representing the Eligible Shares to be sold, and cause such Eligible Shares to be issued in such denominations and registered in such names in accordance
with the underwriting agreement prior to any sale of Eligible Shares to the underwriters; 
 (c) make reasonably available its employees and
personnel for participation in “road shows” and other marketing efforts and otherwise provide reasonable assistance to the underwriters (taking into account the needs of the Company’s businesses and the requirements of the marketing
process) in the marketing of Eligible Shares in such Underwritten Offering; 
 (d) if at any time the information conveyed to a purchaser at
the time of sale includes any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, promptly file with the
SEC such amendments or supplements to such information as may be necessary so that the statements as so amended or supplemented will not, in light of the circumstances, be misleading; 

(e) execute an underwriting agreement in customary form and reasonably acceptable to the Company; and 

(f) subject to all the other provisions of this Agreement, use its reasonable best efforts to take all other steps necessary or advisable to
effect the sale of such Eligible Shares contemplated hereby. 

  
 - 18 - 

 SECTION 7. Expenses. All fees and expenses (other than underwriting discounts and
commissions relating to the Eligible Shares, as provided in this Section 7) incurred by the Company in complying with Section 5 and Section 6, including (i) all registration and filing fees, and any other
fees and expenses associated with filings required to be made with the SEC, FINRA and if applicable, the fees and expenses of any “qualified independent underwriter,” as such term is defined in FINRA Rule 5121 (or any successor provision),
and of its counsel, (ii) all fees and expenses in connection with compliance with any securities or “Blue Sky” laws (including fees and disbursements of counsel for the underwriters in connection with “Blue Sky”
qualifications of the Eligible Shares), (iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses (including expenses of printing certificates for the Eligible Shares in a form eligible for deposit
with The Depository Trust Company and of printing prospectuses), (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold
comfort letters required by or incident to such performance), (v) Securities Act liability insurance or similar insurance if the Company so desires or the underwriters so require in accordance with then-customary underwriting practice,
(vi) all fees and expenses incurred in connection with the listing of Eligible Shares on any securities exchange or quotation of the Eligible Shares on any inter-dealer quotation system, (vii) all applicable rating agency fees with respect
to the Eligible Shares, (viii) any reasonable fees and disbursements of underwriters customarily paid by issuers or sellers of securities, (ix) all fees and expenses of any special experts or other Persons retained by the Company in
connection with any registration, (x) all of the Company’s internal expenses (including all salaries and expenses of its officers and employees performing legal or accounting duties), (xi) all reasonable expenses related to the
“road-show” for any Underwritten Offering, including all travel, meals and lodging of Company personnel or advisors to the Company (not including the underwriters and their advisors), and (xiii) any other fees and disbursements
customarily paid by the issuers of securities shall, in all cases, be paid by the Company (collectively, the “Registration Expenses”); provided, however, that all underwriting discounts and commissions applicable to
the Eligible Shares shall be borne by the Eligible Holders selling such Eligible Shares, in proportion to the number of Eligible Shares sold in the offering by each such Eligible Holder. In addition, in connection with each registration or offering
made pursuant to this Agreement, the Company shall pay the reasonable fees and expenses of Equity Holders’ Counsel. 
 SECTION 8.
Exchange Registration. 
 (a) The Company shall, at its sole expense, file and use reasonable best efforts to effect no later than
the first anniversary of the date of the closing of the initial public offering and sale of Common Stock (as contemplated by the Company’s Registration Statement on Form S-1 (File No. 333-196615)), but subject to Section 8(c) below, a
shelf registration statement on Form S-1 or such other form under the Securities Act then available to the Company providing for the exchange, from time to time, of all Paired Interests held by any Exchange Registration Holder for shares of Common
Stock pursuant to the Exchange Agreement (the “Exchange 

  
 - 19 - 

 
Registration Statement”). Such registration pursuant to this Section 8, including as amended, renewed or replaced as provided in Section 8(b), is referred to
herein as an “Exchange Registration.” 
 (b) The Company shall use its reasonable best efforts to keep the Exchange
Registration Statement continuously effective under the Securities Act and applicable state securities laws until the date as of which no Exchange Registration Holder holds Paired Interests. The filing of the Exchange Registration Statement will not
affect the inclusion of any Registrable Shares in any other registration statement hereunder. In addition, the Company shall promptly amend, renew or replace, as necessary, any Exchange Registration Statement that shall have expired or otherwise
been deemed unusable and shall use its reasonable best efforts to keep such amended, renewed or replaced Exchange Registration Statement continuously effective under the Securities Act and applicable state securities laws until the date as of which
no Exchange Registration Holder holds Paired Interests. For the avoidance of doubt, this Section 8 shall not provide any Exchange Registration Holder the right to request or participate in an offering under Section 2 or
Section 3 or make any exchange of Paired Interests that is prohibited by the Organizational Documents or the LLC Agreement. 

(c) With respect to any Exchange Registration Statement filed, or to be filed, including any amendment, renewal or replacement thereof,
pursuant to this Section 8, if the Company shall furnish to the Exchange Registration Holders a certificate signed by the Chief Executive Officer (or other authorized officer) of the Company stating that in the good faith judgment of the
Executive Committee it would be detrimental to the Company or its stockholders for an Exchange Registration Statement to be filed or used in the near future, in which case the Company’s obligation under Sections 8(a) and 8(b)
shall be deferred for a period not to exceed one hundred and twenty (120) days (provided that the Company shall only be permitted one deferral pursuant to this Section 8(c) in any twelve-month period) and each Exchange Registration
Holder shall keep confidential the fact that such a deferral is in effect, as well as the certificate referred to above and its contents, unless and until otherwise notified by the Company, except (A) for disclosure to such Exchange
Registration Holder’s employees, officers, directors, agents, legal counsel, accountants, auditors and other professional representatives and advisers who reasonably need to know such information solely for purposes of assisting the Exchange
Registration Holder with respect to its investment in Common Stock or Units and agree to keep it confidential, (B) for disclosures to the extent required in order to comply with reporting obligations to its limited partners or other direct or
indirect investors who have agreed to keep such information confidential, (C) if and to the extent such matters are publicly disclosed by the Company or any of its subsidiaries and (D) as required by law, rule or regulation (provided that
the Exchange Registration Holder gives prompt notice of such use in writing, to the extent permitted by law, rule or regulation, and reasonably cooperates with the Company should the Company, at the Company’s sole expense, desire to seek a
protective order or other appropriate remedy to protect the confidentiality of such confidential information prior to disclosure). The Company shall notify the Exchange Registration Holders of the expiration of any period during which it exercised
its rights under this Section 8(c). 

  
 - 20 - 

 SECTION 9. Indemnification. 

(a) In connection with any registration of any Eligible Shares under the Securities Act pursuant to this Agreement, the Company and Desert
Newco, jointly and severally, shall indemnify and hold harmless, to the fullest extent permitted by law, each Eligible Holder, their respective directors, managers, officers, fiduciaries, employees, stockholders, members or general or limited
partners (and the directors, managers, officers, employees and stockholders thereof), each underwriter, broker or any other Person acting on behalf of each Eligible Holder and each other Person, if any, who controls any of the foregoing Persons
within the meaning of the Securities Act from and against any and all losses, claims, damages or liabilities (or actions in respect thereof), joint or several, and expenses reasonably incurred (including reasonable fees of counsel and any amounts
paid in any settlement effected with the Company’s consent, which consent shall not be unreasonably withheld, delayed or conditioned if such settlement is solely with respect to monetary damages) to which any of the foregoing Persons may become
subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) and expenses arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement under which such securities were registered under the Securities Act or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary, final or summary prospectus or any amendment or supplement thereto, together with the documents
incorporated by reference therein, or any free writing prospectus utilized in connection therewith, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, (iii) any untrue statement or alleged untrue statement of a material fact in the information conveyed to any purchaser at the time of the sale to such
purchaser, or the omission or alleged omission to state therein a material fact required to be stated therein in order to make the statements therein not misleading, (iv) any violation by the Company of any federal, state or common law rule or
regulation applicable to the Company and relating to action required of or inaction by the Company in connection with any such registration (including any violation or alleged violation of state “blue sky” laws) or (v) any failure to
register or qualify Eligible Shares in any state where the Company or its agents have affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter being attributed to the Company) will undertake such
registration or qualification on behalf of the Eligible Holders (provided that in such instance the Company shall not be so liable if it has undertaken its reasonable best efforts to so register or qualify such Eligible Shares), and shall
reimburse any such indemnified party for any legal or other expenses reasonably incurred by any of them in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred;
provided, however, that the indemnity agreement contained in this Section 9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), and that the Company shall not be liable to any such indemnified party in any such case to the extent that any such loss, claim, damage, liability or
action (including any legal or other expenses incurred) arises out of or is based upon an untrue statement of a material fact or allegedly untrue statement of a material fact or omission of a 

  
 - 21 - 

 
material fact or alleged omission of a material fact made in said registration statement, preliminary prospectus, final prospectus, amendment, supplement, free writing prospectus or document
incident to registration or qualification of any Eligible Shares in reliance upon and in conformity with written information furnished to the Company by such indemnified party, any Affiliate of such indemnified party or their counsel specifically
for use in the preparation thereof. This indemnity shall be in addition to any liability the Company may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Eligible
Holder or any indemnified party and shall survive the transfer of such securities by such Eligible Holder. The Company shall also indemnify underwriters, selling brokers, dealer managers and similar securities industry professionals participating in
the distribution, their officers and directors and each Person who controls such Persons (within the meaning of the Securities Act and the Exchange Act) to the same extent as provided above with respect to the indemnification of the indemnified
parties. 
 (b) In connection with any registration of Eligible Shares under the Securities Act pursuant to this Agreement, each holder of
Eligible Shares shall severally and not jointly indemnify and hold harmless (in the same manner and to the same extent as set forth in Section 9(a)) to the fullest extent permitted by law the Company, each director or manager of the
Company, each officer of the Company who shall sign such registration statement their respective directors, officers, fiduciaries, employees, stockholders, members or general or limited partners (and the directors, officers, employees and
stockholders thereof), and each Person who controls any of the foregoing Persons within the meaning of the Securities Act with respect to any untrue statement of a material fact or omission of a material fact required to be stated therein in order
to make the statements therein not misleading, from such registration statement, any preliminary prospectus or final prospectus contained therein or otherwise filed with the SEC, any amendment or supplement thereto, any free writing prospectus
utilized thereunder or any document incident to registration or qualification of any Eligible Shares, but only if such statement or omission was made in reliance upon and in conformity with written information furnished to the Company by such holder
specifically for use in connection with the preparation of such registration statement, preliminary prospectus, final prospectus, amendment, supplement or document; provided, however, that the indemnity agreement contained in this
Section 9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Eligible Holder (which consent shall not be unreasonably withheld,
delayed or conditioned), and that the maximum amount of liability in respect of such indemnification shall be limited, in the case of each seller of Eligible Shares, to an amount equal to the net proceeds actually received by such seller from the
sale of Eligible Shares effected pursuant to such registration giving rise to such loss, claim, damage, liability, action or expense. 
 (c)
Promptly after receipt by an indemnified party of notice of the commencement of any action or proceeding that may involve a claim referred to in the preceding paragraphs of this Section 9, such indemnified party will give written notice
to the latter of the commencement of such action. The failure of any indemnified party to notify an indemnifying party of any such action shall not relieve the indemnifying party from any liability in respect of such action that it may have to such
indemnified party on account of this Section 9, except to the extent the indemnifying party is materially prejudiced thereby. In case any such action is 

  
 - 22 - 

 
brought against an indemnified party, the indemnifying party will be entitled to participate in and to assume the defense thereof, jointly with any other indemnifying party similarly notified to
the extent that it may wish, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be
responsible for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that if (i) the indemnifying party
fails to take reasonable steps necessary to defend diligently the action or proceeding within twenty (20) days after receiving notice from such indemnified party; or (ii) counsel to an indemnified party shall have reasonably concluded that
there may be one or more legal or equitable defenses available to such indemnified party which are additional to or conflict with those available to the indemnifying party; or (iii) representation of both parties by the same counsel is
otherwise inappropriate under applicable standards of professional conduct, then in any such case the indemnifying party shall not have the right to assume the defense of such action on behalf of such indemnified party (but shall have the right to
participate therein with counsel of its choice at its own expense) and such indemnifying party shall reimburse such indemnified party and any Person controlling such indemnified party for the reasonable fees and expenses of any counsel retained by
the indemnified party which is reasonably related to the matters covered by the indemnity agreement provided in this Section 9. If the indemnifying party is not entitled to, or elects not to, assume the defense of a claim, it will not be
obligated to pay the reasonable fees and expenses of more than one counsel with respect to such claim. 
 (d) No indemnifying party shall,
without the written consent of the indemnified party (which consent shall not be unreasonably withheld, delayed or conditioned), effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or
threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment
(A) includes an unconditional release of the indemnified party from all liability arising out of such action or claim, and (B) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of
any indemnified party. 
 (e) If the indemnification provided for in this Section 9 is unavailable to or is insufficient to hold
harmless an indemnified party with respect to any loss, claim, damage, liability, action or expense referred to herein, then the indemnifying party shall contribute to the amounts paid or payable by such indemnified party as a result of such loss,
claim, damage, liability, action or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the untrue or alleged untrue
statements of a material fact or omissions or alleged omissions to state a material fact which resulted in such loss, claim, damage, liability, action or expense as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact required to be
stated in any communications in order to make the statements therein not misleading, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and

  
 - 23 - 

 
opportunity to correct or prevent such statement or omission. The parties agree that it would not be just and equitable if contribution pursuant hereto were determined by pro rata allocation or
by any other method or allocation which does not take account of the equitable considerations referred to herein. No Person guilty of fraudulent misrepresentation shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation. Notwithstanding anything in this Section 9(e) to the contrary, no Eligible Holder shall be required to contribute any amount in excess of the proceeds (net of expenses and underwriting discounts and
commissions) received by such Eligible Holder from the sale of the Registrable Shares in the offering to which the losses, claims, damages, liabilities and expenses of the indemnified parties relate less the amount of any indemnification payment
made by such Eligible Holder pursuant to Section 9(b). 
 SECTION 10. Underwritten Offerings. In the case of a
registration pursuant to Section 2 or Section 3 hereof, if the Company is entering into a customary underwriting or similar agreement in connection therewith, all of the Eligible Shares to be included in such registration
shall be subject to such underwriting agreement. To the extent required, the Eligible Holders shall enter into an underwriting or similar agreement, which agreement may contain provisions covering one or more issues addressed herein, and, in the
case of any conflict with the provisions hereof, the provisions contained in such underwriting or similar agreement addressing such issue or issues shall control. In the case of an Underwritten Offering under Section 2 hereof, the price,
underwriting discount and other financial terms for the Eligible Shares shall be determined by the Requesting Equity Holders or the Initiating Equity Holders, as applicable, in such Underwritten Offering. 

SECTION 11. Information by Eligible Holders. Each Eligible Holder and, in the case of Section 8, Exchange Registration Holder,
shall furnish to the Company such written information regarding such Eligible Holder and Exchange Registration Holder, as applicable, and the distribution proposed by the Eligible Holder as the Company may reasonably request in writing and as shall
be reasonably required in connection with any registration, qualification or compliance referred to in this Agreement. 
 SECTION 12.
Delay of Registration. No Eligible Holder or Exchange Registration Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with
respect to the interpretation or implementation of this Agreement. 
 SECTION 13. Exchange Act Compliance. With a view to making
available the benefits of certain rules and regulations of the SEC which may permit the sale of restricted securities to the public without registration, the Company agrees to: 

(a) make and keep public information available as those terms are understood and defined in Rule 144, at all times from and after ninety
(90) days following the effective date of the registration statement with respect to the IPO; 
 (b) use its reasonable best efforts to
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and 

  
 - 24 - 

 (c) so long as the Eligible Holders own any Registrable Shares, furnish to the Eligible Holders
upon request, a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective date of the registration statement with respect to the IPO),
and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as an
Eligible Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing such Eligible Holder to sell any such securities without registration. 

SECTION 14. Termination of Registration Rights. With respect to each Eligible Holder, the registration rights set forth in this
Agreement will terminate at such time as such Eligible Holder and its successors (and its affiliates, partners and former partners) no longer hold any Eligible Shares (the “Rights Termination Date”); provided that, for the
avoidance of doubt, if a Rights Termination Date with respect to any Eligible Holder occurs during a Holdback Period, such Eligible Holder will continue to be bound by the provisions set forth in Section 4 until the end of such Holdback
Period; and provided further, that upon exercise by the Company of any postponement right hereunder, the period during which any Eligible Holder may exercise any rights provided for in this Agreement shall be extended for a period
equal to the period of such postponement by the Company. Each Exchange Registration Holder’s rights set forth in this Agreement will terminate at such time as such Exchange Registration Holder and its successors (and its affiliates, partners
and former partners) no longer hold any Paired Interests. 
 SECTION 15. Successors and Assigns; Third Party Beneficiaries. This
Agreement shall bind and inure to the benefit of the Company, the Equity Holders, the Exchange Registration Holders and, subject to Section 16, the respective successors and assigns of the Company, the Equity Holders and the Exchange
Registration Holders. Except for those provisions hereunder applicable to Other Shares and holders of Other Shares, with respect to which any holder of Other Shares shall be a third party beneficiary if and to the extent such holder of Other Shares
has agreed to be bound by such provisions, and except for the provisions of Section 9 hereof, with respect to which any Person indemnified thereby shall be a third party beneficiary, no other third party beneficiaries are intended or
shall be deemed to be created hereby. 
 SECTION 16. Assignment. Any Equity Holder or Exchange Registration Holder may assign its
rights hereunder, in whole or in part, to any Affiliate or third party to whom such Equity Holder or Exchange Registration Holder transfers (other than in a public offering, Rule 144 sale or other anonymous transfer) Registrable Shares or Paired
Interests in accordance with the Company’s Organizational Documents, the LLC Agreement and the Stockholder Agreement (as defined in the LLC Agreement), as applicable (an “Assignee”); provided, however, that such
third party shall, as a condition to the effectiveness of such assignment, be required to execute a counterpart to this Agreement agreeing to be treated as an Equity Holder or Exchange Registration Holder, as applicable, whereupon such third party
shall have the benefits of, and shall be subject to the restrictions contained in, this Agreement as if such third party was originally included in the definition of Equity Holder or Exchange Registration Holder, as applicable, and had originally
been a party hereto (including any benefits and restrictions expressly applicable to the assigning Equity Holder); provided further, that, with respect to any 

  
 - 25 - 

 
transfer of Registrable Shares or Paired Interests that pursuant to the Company’s Organizational Documents, the LLC Agreement and the Stockholder Agreement (as defined in the LLC Agreement)
requires the consent of the Company or any other Person(s), such transfer may be conditioned upon the transferee not becoming an Assignee hereunder, and such equity securities no longer being Registrable Shares hereunder. 

SECTION 17. Entire Agreement. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof
and supersedes all prior agreements and undertakings, both written and oral, among the parties with respect to the subject matter hereof, except for contracts and agreements referred to herein. 

SECTION 18. Notices. All notices, requests and other communications to any party hereunder shall be in writing (including facsimile
transmission and electronic mail (“e-mail”) transmission, so long as a receipt of such e-mail is requested and received by non-automated response). All such notices, requests and other communications shall be delivered in person or
sent by facsimile, e-mail or nationally recognized overnight courier and shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a business day in the place of receipt. Otherwise, any such notice,
request or communication shall be deemed to have been received on the next succeeding business day in the place of receipt. All such notices, requests and other communications to any party hereunder shall be given to such party as follows: 

(i) If to the Company or Desert Newco, to: 

c/o GoDaddy Inc. 

[            ] 

with a copy (which shall not constitute notice) to: 

Wilson Sonsini Goodrich & Rosati 

[            ] 

(ii) If to the KKR Group, to: 

Kohlberg Kravis Roberts & Co. L.P. 

[            ] 

with a copy (which shall not constitute notice) to: 

Simpson Thacher & Bartlett LLP 

[            ] 

(iii) If to the Silver Lake Group, to: 

Silver Lake Partners 

[            ] 

  
 - 26 - 

 and to: 

Silver Lake Partners 

[            ] 

with a copy (which shall not constitute notice) to: 

Simpson Thacher & Bartlett LLP 

[            ] 

(iv) If to the TCV Group, to: 

Technology Crossover Ventures 

[            ] 

with a copy (which shall not constitute notice) to: 

Kirkland & Ellis LLP 

[            ] 

(v) If to the Holdings Group, to: 

The Go Daddy Group, Inc. 
 c/o
YAM Management LLC 
 [            ] 

with a copy (which shall not constitute notice) to: 

DeCastro, West, Chodorow, Glickfeld & Nass, Inc. 

[            ] 

(vi) If to the Qatalyst Group, to: 

QCP Fund C LP c/o Qatalyst Group 

[            ] 

(vii) If to the WSGR Group, to: 

Wilson Sonsini Goodrich & Rosati 

Professional Corporation 

[            ] 

  
 - 27 - 

 (viii) If to Employee Holdco or a member of Employee Holdco, to: 

c/o Desert Newco Managers, LLC 

[            ] 

with a copy (which shall not constitute notice) to: 

Wilson Sonsini Goodrich & Rosati 

Professional Corporation 

[            ] 

(viii) If to any other Exchange Registration Holder, to the address(es) set forth in Desert Newco’s Schedule of Members, 

or to such other address or to the attention of such Person or Persons as the recipient party has specified by prior written notice to the sending party (or
in the case of counsel, to such other readily ascertainable business address as such counsel may hereafter maintain). If more than one method for sending notice as set forth above is used, the earliest notice date established as set forth above
shall control. 
 SECTION 19. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of
being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible within a reasonable period
of time. 
 SECTION 20. Modifications; Amendments; Waivers. The terms and provisions of this Agreement may not be modified or
amended, nor may any provision be waived, except pursuant to a writing signed by the Company and each of the Sponsors whose Group then holds Registrable Securities; provided that any such modification, amendment or waiver that
(i) repeals, nullifies, eliminates or adversely modifies any right expressly granted to an Equity Holder individually in this Agreement (as opposed to rights granted to the Equity Holders or any group of Equity Holders generally) or
(ii) adversely impacts the economic powers, rights, preferences or privileges of an Equity Holder hereunder relative to any other Equity Holder, shall, in each case, require the written consent of such Equity Holder; provided,
further that any such modification, amendment or waiver to Section 8 hereof that adversely impacts the rights of the Exchange Registration Holders shall require the consent of holders of a majority in interest of shares of Common
Stock issuable upon exchange of the Paired Interests held directly by, or by Employee Holdco on behalf of, the Exchange Registration Holders other than Employee Holdco. Each Exchange Registration Holder who is not party to this Agreement as of its
original date shall automatically become party hereto upon the execution and delivery of a counterpart 

  
 - 28 - 

 
signature page or joinder hereto, and such execution and delivery shall not require the consent of any other party hereto and shall not be deemed to be an amendment or modification to this
Agreement. 
 SECTION 21. Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties
hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 

SECTION 22. Headings; Exhibits. The headings contained in this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. All exhibits and annexes attached hereto are incorporated in and made a part of this Agreement as if set forth in full herein. 

SECTION 23. Governing Law. This Agreement shall be construed in accordance with and governed by the laws of the State of Delaware,
without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of Delaware. 

SECTION 24. Waiver of Jury Trial; Consent to Jurisdiction. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE TO THE FULLEST EXTENT
PERMITTED BY LAW ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. Each party hereby irrevocably submits to the exclusive jurisdiction of the
federal courts located in the State of Delaware or the Delaware Court of Chancery for the purpose of adjudicating any dispute arising hereunder. Each party hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such
court any objection to such jurisdiction, whether on the grounds of hardship, inconvenient forum or otherwise. Each party further agrees that service of any process, summons, notice or document by U.S. registered mail to such party’s respective
address set forth in Section 18 shall be effective service of process for any action, suit or proceeding with respect to any matters to which it has submitted to jurisdiction in this Section 24. 

SECTION 25. Mergers and Other Transactions Affecting Registrable Securities. The provisions of this Agreement shall apply to the full
extent set forth herein with respect to the Registrable Securities, to any and all securities or units of the Company or Desert Newco or any successor or assign of any such person (whether by merger, amalgamation, consolidation, sale of assets or
otherwise) that may be issued in respect of, in exchange for, or in substitution of such securities, by reason of any dividend, split, issuance, reverse split, combination, recapitalization, reclassification, merger, amalgamation, consolidation or
otherwise. 
 [Signature page follows] 

  
 - 29 - 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the date
first above written. 
  

	
	[SIGNATURE PAGES AND ANNEX TO COME]

 ANNEX I 

QATALYST RELATED PARTIESEX-4.6

 Exhibit 4.6 
 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the Securities and Exchange Commission. 
 NIKON-ASML PATENT CROSS-LICENSE AGREEMENT 
 THIS NIKON-ASML PATENT CROSS-LICENSE AGREEMENT
(this “AGREEMENT”) is made and entered into as of November 12, 2004 (the “EFFECTIVE DATE”) by and between ASML Holding N.V., a corporation organized under the laws of the Netherlands (“ASML”), and Nikon
Corporation, a corporation organized under the laws of Japan (“NIKON”). ASML and Nikon are hereinafter also referred to collectively as the “PARTIES” and individually as a “PARTY.” 

RECITALS 
 WHEREAS, Nikon, ASML and Zeiss
SMT entered into a Memorandum of Understanding entered into as of September 27, 2004 (“MOU”), pursuant to which they agreed, among other things, to settle certain litigation proceedings and grant cross-licenses of certain patent
rights; and 
 WHEREAS, pursuant to the MOU, Nikon and ASML are entering into that certain Nikon-ASML Settlement and Release Agreement of even
date herewith (the “NIKON-ASML SETTLEMENT AND RELEASE AGREEMENT”); 
 NOW, THEREFORE, the Parties agree as follows: 

AGREEMENT 
 1. DEFINITIONS;
INTERPRETATION 
 1.1 Terms Defined in this Agreement. The following terms when used in this Agreement shall have the following definitions:

 1.1.1 “ACQUIRED PATENT” is defined in Section 1.2.7. 
 1.1.2 “ACQUIRING PARTY” is defined in Section 1.2.7. 
 1.1.3 “AFFILIATE”
means, with respect to any Person, any other Person that controls, is controlled by or is under common control with such first Person, but only for such time as control exists. For this purpose control of a Person means possession, directly or
indirectly, of the power to direct or cause the direction of management, business affairs or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise). 

1.1.4 “AGREEMENT TERM” means the period commencing on the Effective Date and ending on December 31, 2014. 

1.1.5 “ARBITRATION AGREEMENT” means the Arbitration Agreement dated as of the Effective Date by and among Nikon, ASML, Zeiss SMT, and Carl
Zeiss. 
 1.1.6 “ASML LICENSED PATENTS” is defined in Section 1.2.5. 
 1.1.7 “ASML LICENSED PRODUCTS” is defined in Section 1.3.1 
 1.1.8 “ASSERTING
PARTY” is defined in Section 4.2.1. 
 1.1.9 “CARL ZEISS” means Carl Zeiss AG, a corporation organized under the laws of
Germany. 
 1.1.10 “CLASS A PATENT” is defined in Section 1.2.7. 

  

					
		  	1	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.1.11
“CLASS B PATENT” is defined in Section 1.2.8. 
 1.1.12 “CLASS C PATENT” is defined in Section 1.2.9. 

1.1.13 “CO-OWNED” (and the correlative “CO-OWNER”) is defined in Section 1.2.11. 

1.1.14 “CONVERTIBLE PATENTS” is defined in Section 1.2.3. 
 1.1.15 “COVERED ENTITIES” of a Party means, with respect to a Licensed Product, the direct and indirect resellers, distributors, users and other customers of such Licensed Product of such Party
and/or its Subsidiaries, and any Person acquiring such Licensed Product from any of the foregoing. 
 1.1.16 “DESIGNATED NEUTRAL”
means the Honorable Edward Infante, or if he is unable or unwilling to perform the relevant function, a substitute of comparable experience who is mutually agreeable to the Parties. 
 1.1.17 “DESIGNATED NIKON PATENTS” means the three (3) Patent applications listed on Schedule E hereto. 
 1.1.18 “DIRECT OR INDIRECT SALE” means the sale, lease, or other conveyance of a product by a Party or its Subsidiaries to a third Person, or the sale, lease, or other conveyance of a product by
a Party or its Subsidiaries to another Person which in turn sells, leases, or otherwise conveys such product to the third Person substantially in the form acquired from such Party or its Subsidiaries. 

1.1.19 “E-BEAM LITHOGRAPHY” means electron beam lithography or other charged particle beam lithography, including direct write electron beam
lithography. 
 1.1.20 “EFFECTIVE APPLICATION DATE” of a Patent application means the earliest of (a) the filing date of such
application, and (b), in the event that such application claims priority from the filing date of an earlier filed application or applications (including provisional applications), the earliest (i) filing date of any of such earlier filed
application or applications, and (ii) for all of such earlier filed applications that make further priority claims to earlier dates, the Effective Application Dates of such earlier filed applications. 

1.1.21 “ELIGIBLE NIKON PATENT FAMILY” is defined in Section 1.2.21 
 1.1.22 “ELIGIBLE NIKON PATENT FAMILY MEMBER” is defined in Section 1.2.22. 
 1.1.23
“EXCESS ASSERTION” is defined in Section 2.8.5(b). 
 1.1.24 “EXCLUDED CLAIM” is defined in Section 1.2.15.

 1.1.25 “EXCLUDED CLAIM CRITERIA” is defined in Section 1.2.16. 
 1.1.26 “EXCLUDED CLAIMS LIST” is defined in Section 2.3.1. 
 1.1.27 “EXCLUDED
GLASS METHODS” means all methods or processes for making Excluded Glass Products described in subclauses (a) and (b) of Section 1.1.28. 

  

					
		  	2	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.1.28
“EXCLUDED GLASS PRODUCTS” means (a) optical material, including glass, silica glass, crystal, and calcium fluoride crystal, but not including optical coatings, (b) optical blanks, and (c) unfinished lenses purchased by a
Party or its Subsidiaries from third parties other than Zeiss SMT and its Subsidiaries. 
 1.1.29 “EXCLUDED LITHOGRAPHY TECHNOLOGY” is
defined in Section 1.2.1. 
 1.1.30 “EXCLUDED NIKON PATENTS” is defined in Section 1.2.20. 

1.1.31 “FINALLY RESOLVED” (and the correlative, “FINAL RESOLUTION”) with respect to a Suit, means that such Suit is (a) settled
and dismissed with prejudice, (b) subject to a final judgment as to which no appeal is possible or taken within the time permitted, or (c) is withdrawn completely by the Person bringing such Suit. 

1.1.32 “FPD/LARGE AREA SUBSTRATE LITHOGRAPHY” means lithography to manufacture flat panel displays or expose large area substrates other than
wafers (i.e., substrates other than wafers that are greater than 500mm along any dimension). 
 1.1.33 “FULL RIGHTS TERMINATION” is
defined in Section 2.8.4. 
 1.1.34 “GLASS SUPPLIER” is defined in Section 4.2.2. 

1.1.35 “GOVERNMENTAL AUTHORITY” means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi governmental authority of any nature (including any governmental division, subdivision, department,
agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); or (d) individual, entity or body exercising, or entitled to
exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. 

1.1.36 “INDEPENDENT AUDITOR” shall have the meaning set forth in Section 5.5. 
 1.1.37 “LAW” means any law, statute, legislation, constitution, principle of common law, resolution, ordinance, code, order, edict, decree, proclamation, treaty, convention, rule, regulation,
ruling, directive, pronouncement, requirement (licensing or otherwise), determination, decision, opinion or interpretation that is, has been or may in the future be issued, enacted, adopted, passed, approved, promulgated, made, implemented or
otherwise put into effect by or under the authority of any Governmental Authority. 
 1.1.38 “LICENSABLE CO-OWNED PATENT” is defined
in Section 1.2.12. 
 1.1.39 “LICENSE TERM” means the period commencing on the Effective Date and ending on December 31,
2009. 
 1.1.40 “LICENSED PATENTS” is defined in Section 1.2.6. 
 1.1.41 “LICENSED PRODUCTS” is defined in Section 1.3.3. 

  

					
		  	3	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.1.42
“LITHOGRAPHY” is defined in Section 1.3.4. 
 1.1.43 “LITHOGRAPHY EQUIPMENT” is defined in Section 1.3.5.

 1.1.44 “LITHOGRAPHY PATENT” is defined in Section 1.2.2. 
 1.1.45 “MASKLESS LITHOGRAPHY” means Lithography in which light is patterned using individually-controllable elements and not a reflective or transmissive mask. 

1.1.46 “MOU” shall have the meaning set forth in the recitals. 
 1.1.47 “NET SELLING PRICE” means the gross revenues actually received by a Party or its Subsidiaries from Direct or Indirect Sales of a product, less (a) normal and customary rebates, and
cash and trade discounts; (b) sales, use and/or other excise taxes or duties; (c) insurance costs and outbound transportation charges; (d) import and/or export duties; and (e) amounts allowed or credited due to returns (not to
exceed the original billing or invoice amount). 
 1.1.48 “NIKON-ASML SETTLEMENT AND RELEASE AGREEMENT” shall have the meaning set
forth in the recitals. 
 1.1.49 “NIKON-ZEISS PATENT CROSS-LICENSE AGREEMENT” means that certain Nikon-Zeiss Patent Cross-License
Agreement by and between Nikon and Zeiss SMT of even date herewith, as amended from time to time. 
 1.1.50 “NIKON DEFENSIVE SUIT” is
defined in Section 2.8.5(a). 
 1.1.51 “NIKON LICENSED PATENTS” is defined in Section 1.2.4. 

1.1.52 “NIKON LICENSED PRODUCTS” is defined in Section 1.3.6. 
 1.1.53 “OPTICAL COMPONENTS” means (a) optical elements, modules and systems, including illumination optical systems, projection optical systems, manipulation devices and mounting means, and
(b) processes, materials and devices for designing, manufacturing, assembling, adjusting, measuring and qualifying such optical elements, modules and systems, in each case for Lithography Equipment. 

1.1.54 “OWNED” (and the correlative “OWNERSHIP”) is defined in Section 1.2.10. 

1.1.55 “PATENTS” means all classes or types of patents (including design patents) and utility models of all countries of the world, and
applications therefor, together with any divisionals, continuations, continuations-in-part, reissues and results of re-examinations thereof. 

1.1.56 “PAYMENTS” shall have the meaning set forth in Section 5.1. 
 1.1.57 “PERSON” means any person or entity, whether an individual, corporation, partnership, limited partnership, limited liability company, trust, foundation, unincorporated organization,
business association, firm, joint venture or other legal entity. 
 1.1.58 “PRACTICALLY USABLE EMBODIMENTS” shall have the meaning set
forth in Section 1.2.16. 

  

					
		  	4	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.1.59
“PURCHASING PARTY” shall have the meaning set forth in Section 4.2.2(a). 
 1.1.60 “RESTRICTED PATENT” is defined in
Section 1.2.13. 
 1.1.61 “RUNNING ROYALTY PAYMENTS” is defined in Section 4.2.2(b)(v). 

1.1.62 “SCHEDULE D OMITTED CLAIMS” is defined in Section 1.2.18. 
 1.1.63 “SCHEDULE D PATENTS” is defined in Section 1.2.17. 
 1.1.64 “SCHEDULE D
PATENT FAMILY” is defined in Section 1.2.18. 
 1.1.65 “SCHEDULE D PATENT FAMILY MEMBER” is defined in Section 1.2.19.

 1.1.66 “SCHEDULE D RESPONSE” is defined in Section 2.8.5(c). 
 1.1.67 “SCHEDULE D SUIT” is defined in Section 2.8.5(c). 
 1.1.68 “SPECIAL
MASK TECHNOLOGY” means (i) a pattern on a mask having a modified shape (as compared to the desired shape of the pattern to be printed on the substrate), where such modification is made for the purpose of forming a circuit pattern onto a
substrate (“SPECIAL PATTERN”); (ii) a mask with a Special Pattern, modified transmittance (as compared to a binary mask) or modified phase (as compared to a binary mask), where such modification is made for the purpose of forming a
circuit pattern onto a substrate (“SPECIAL MASK”); (iii) a method of exposing a substrate using a Special Mask; (iv) a method of manufacturing a semiconductor chip using a Special Mask; (v) a method of manufacturing a
Special Mask; or (vi) data processing hardware, software, methods or processes used to analyze, simulate, predict, generate or modify pattern data used on a Special Mask. 
 1.1.69 “SPECIFICALLY DIRECTED TO” shall have the meaning set forth in Section 1.2.16. 
 1.1.70 “SPECIFIED ENTITY” shall mean the Person listed in Schedule F. 
 1.1.71
“SPECIFIED ENTITY SUIT” is defined in Section 2.8.5(a). 
 1.1.72 “SUBLICENSABLE” is defined in Section 1.2.14.

 1.1.73 “SUBLICENSOR” is defined in Section 1.2.14. 
 1.1.74 “SUBSIDIARY” of a Person means any other Person with respect to which such first Person has beneficial ownership, directly or indirectly, of securities representing more than fifty
percent (50%) of the power to elect such other Person’s board of directors or other managing authority or, in the case of a non-corporate Person, equivalent interests. 
 1.1.75 “SUE” means (a) to threaten, bring, or participate in any legal or equitable action, claim or demand in any court or before any tribunal or any arbitration or compulsory and binding
alternative dispute resolution proceeding, either directly or indirectly, or (b) to instruct, request, encourage, or assist any designee, agent, nominee or other third party to do the same, unless legally compelled to do so by a valid subpoena
or court order which the recipient has opposed by all reasonable means. “Sue” shall not be construed to include offers to license Patents in connection with cross-license or other license negotiations. 

  

					
		  	5	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.1.76
“SUIT” means any legal or equitable action, claim or demand in any court or before any tribunal or any arbitration or compulsory and binding alternative dispute resolution proceeding, or any threat thereof, but not including offers to
license Patents in connection with cross-license or other license negotiations. 
 1.1.77 “TRANSACTION AGREEMENTS” is defined in
Section 10.6. 
 1.1.78 “TRANSFER” shall have the meaning set forth in Section 9.3. 

1.1.79 “TRANSFEREE” shall have the meaning set forth in Section 9.3. 
 1.1.80 “TRANSITION PERIOD” means the period beginning upon the end of the License Term and ending at the end of the Agreement Term. 
 1.1.81 “WITHHOLDINGS” shall have the meaning set forth in Section 5.2. 
 1.1.82
“ZEISS SMT PAYMENTS” shall have the meaning set forth in Section 8.2.2. 
 1.1.83 “ZEISS SMT” means Carl Zeiss SMT AG,
a corporation organized under the laws of Germany. 
 1.2 Additional Definitions Relating to Licensed Patents. 

1.2.1 “EXCLUDED LITHOGRAPHY TECHNOLOGY” means each of E-Beam Lithography, FPD/Large Area Substrate Lithography, and Maskless Lithography.

 1.2.2 “LITHOGRAPHY PATENT” means any Patent (a) that either (i) issues from an application having an Effective
Application Date on or before December 31, 2002, or (ii) issues on or before December 31, 2014 from an application having an Effective Application Date after December 31, 2002, and (b) has one or more claims, other than
Excluded Claims, which read on Lithography Equipment or the manufacture or use thereof. For purposes of Section 6.3 only, a Patent application shall not constitute a “Lithography Patent” unless and until such Patent application is
published. 
 1.2.3 “CONVERTIBLE PATENTS” means, with respect to Patents of a Party or its Subsidiaries, (i) Class B Patents that
are Licensed Patents of such Party, and (ii) any Class C Patents of such Party. 
 1.2.4 “NIKON LICENSED PATENTS” means all
Class A Patents and Class B Patents Owned or Sublicensable by Nikon or its Subsidiaries, excluding any Excluded Claims thereof and excluding, subject to Section 2.8.3, all Excluded Nikon Patents. 

1.2.5 “ASML LICENSED PATENTS” means all Class A Patents and Class B Patents Owned or Sublicensable by ASML or its Subsidiaries, excluding
any Excluded Claims thereof. 
 1.2.6 “LICENSED PATENTS” means the ASML Licensed Patents or the Nikon Licensed Patents, as applicable.
For purposes of this Agreement, the Licensed Patents “of” ASML 

  

					
		  	6	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 and/or its
Subsidiaries means the ASML Licensed Patents and the Licensed Patents “of” Nikon and/or its Subsidiaries means the Nikon Licensed Patents, and the Licensed Patents “of” a Party and/or its Subsidiaries means the ASML Licensed
Patents and/or the Nikon Licensed Patents, as applicable. 
 1.2.7 “CLASS A PATENT” means (a) a Patent that issues at any time
(whether before or after the end of the License Term) from an application having an Effective Application Date on or before December 31, 2002, and (b) a Convertible Patent that is converted by a Party pursuant to and in accordance with
Section 2.5. Notwithstanding subsection (a) above, a Patent of a Party that is purchased or otherwise acquired by such Party (“ACQUIRING PARTY”) from a third party (other than an Affiliate of such Party), whether by assignment,
merger, acquisition of assets or otherwise, after the Effective Date, and that otherwise qualifies as a Licensed Patent (“ACQUIRED PATENT”), shall be deemed to be a Class B Patent and not a Class A Patent, regardless of its Effective
Application Date (unless such Patent is converted to a Class A Patent by a Party in accordance with Section 2.5); provided, however, that this sentence shall not apply to any Schedule D Patent Family Member or any Patent that the Specified
Entity or any of its Affiliates has or had an obligation to assign to ASML or any of its Subsidiaries. Notwithstanding anything to the contrary in this Section 1.2.7, if (i) the Acquired Patent issues with the Acquiring Party being
identified on the face of the Acquired Patent or by patent office records as the initial owner or assignee of record of such issued Acquired Patent, and (ii) such Acquired Patent qualifies as a Class A Patent by virtue of its Effective
Application Date, then such issued Acquired Patent shall be deemed a Class A Patent unless the Acquiring Party provides express written notice to the other Party that such Patent is an Acquired Patent within three (3) months of the
issuance of such Acquired Patent. 
 1.2.8 “CLASS B PATENT” means (a) a Patent that issues on or before the end of the License
Term from an application having an Effective Application Date after December 31, 2002, excluding (b) any such Patent that is converted to a Class A Patent by a Party pursuant to and in accordance with Section 2.5. Notwithstanding
subsection (a) above, an Acquired Patent shall be deemed to be a Class B Patent and not a Class A Patent, regardless of its Effective Application Date (unless such Patent is converted to a Class A Patent by a Party in accordance with
Section 2.5); provided, however, that this sentence shall not apply to any Schedule D Patent Family Member or any Patent that the Specified Entity or any of its Affiliates has or had an obligation to assign to ASML or any of its Subsidiaries.
Notwithstanding anything to the contrary in this Section 1.2.8, if (i) the Acquired Patent issues with the Acquiring Party being identified on the face of the Acquired Patent or by patent office records as the initial owner or assignee of
record of such issued Acquired Patent, and (ii) such Acquired Patent qualifies as a Class A Patent by virtue of its Effective Application Date, then such issued Acquired Patent shall be deemed a Class A Patent unless the Acquiring
Party provides express written notice to the other Party that such Patent is an Acquired Patent within three (3) months of the issuance of such Acquired Patent. 
 1.2.9 “CLASS C PATENT” means a Patent having an Effective Application Date after December 31, 2002 and issuing during the Transition Period that would be an ASML Licensed Patent or Nikon
Licensed Patent, as applicable, had such Patent issued on or before the end of the License Term. 
 1.2.10 “OWNED” (and the
correlative “OWNERSHIP”) means, with respect to a Patent of a Person, (a) a Patent that is solely assigned to and/or solely owned by such Person (without regard to rights that employees may have in inventions that they develop while
employed by a Party, such as, for example, the right to receive monetary compensation or assert preemptive rights), or (b) a Licensable Co-Owned Patent. A Patent shall not be deemed “Owned” by the applicable Party to the extent and as
long as it is a Restricted Patent. 

  

					
		  	7	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.2.11
“CO-OWNED” (and the correlative “CO-OWNERS”) means, with respect to a Patent, a Patent that has been assigned to two or more Persons or in which two or more Persons have an ownership interest. 

1.2.12 “LICENSABLE CO-OWNED PATENT” means (a) a Patent that is Co-Owned by a Party or its Subsidiaries and all other Co-Owners of which
are Affiliates of such Party or its Subsidiaries, (b) a Patent that is Co-Owned by ASML and/or its Subsidiaries and all other Co-Owners of which are Zeiss SMT and/or its Subsidiaries, and (c) a Patent that is Co-Owned by a Party or its
Subsidiaries and where any other Co-Owner is a third party (other than an Affiliate of such Party) as to which, and only to the extent and for such time as, and subject to the conditions under which, such Party or its Subsidiaries have the right to
grant licenses, immunities, and additional commitments within the scope of the licenses and immunities granted under this Agreement (i) without such grant requiring consent of any such third party, or (ii), where such grant requires consent of
any such third party or parties, if and to the extent such consent is or has been granted by all such third parties. 
 1.2.13 “RESTRICTED
PATENTS” means (a) any Patent that (i) is listed on Schedule B-1 or Schedule C-1, as applicable (as initially attached hereto, and not as such Schedules may be amended pursuant to Section 6.5 or otherwise), or (ii) is
published after the Effective Date and results from activities funded by a Governmental Authority, in each case where the license of such Patent to third parties is generally prohibited under applicable Law or the applicable contract with such
Governmental Authority in accordance with the standard procedures of such Governmental Authority, but only as long as such prohibition shall remain in force and effect, and (b) any Patent that is (i) Co-Owned by a Party or its Subsidiaries
and one or more third parties, and (ii) not a Licensable Co-Owned Patent, but only as long as, and solely to the extent that, it is not a Licensable Co-Owned Patent. 
 1.2.14 “SUBLICENSABLE” means, with respect to a Patent licensed or sublicensed to a Party or any of its Subsidiaries (as applicable, the “SUBLICENSOR”), a Patent as to which, and only
to the extent and for such time as, and subject to the conditions under which, the Sublicensor has the right to grant licenses or sublicenses, and extend immunities and additional commitments, to the other Party and its Subsidiaries and their
respective Covered Entities within the scope of the licenses, immunities, and additional commitments granted or made under this Agreement without such grant resulting in the payment of royalties or other payments to third parties, except for
payments (i) relating to the prosecution or maintenance of Patents, (ii) to Affiliates of the Sublicensor, or (iii) to Persons for inventions made by such Persons while employees or contractors of the Sublicensor. 

1.2.15 “EXCLUDED CLAIM” means any Patent claim that: 
 (a) is contained on the Excluded Claims List, unless and until such Patent claim ceases to meet the Excluded Claim Criteria as set forth in Section 2.3.2; or 

(b) is not contained on the Excluded Claims List, but meets the Excluded Claim Criteria, but only for so long as such Patent claim meets the Excluded
Claim Criteria; or 
 (c) reads only on Excluded Glass Products or Excluded Glass Methods (provided that Patent claims reading only on
unfinished lenses shall constitute Excluded Claims solely with respect to unfinished lenses purchased by a Party or its Subsidiaries from third parties other than Zeiss SMT and its Subsidiaries); or 

(d) includes any Special Mask Technology as a required element that is material to the patentability of such claim. 

  

					
		  	8	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.2.16
“EXCLUDED CLAIM CRITERIA” with respect to a Patent claim shall be deemed met if such Patent claim is Specifically Directed To equipment or methods for an Excluded Lithography Technology. A Patent claim shall be deemed to be
“SPECIFICALLY DIRECTED TO” equipment or methods for an Excluded Lithography Technology if, and only for so long as, 
 (i) the
embodiments of the Patent claim that are practically usable in a commercial setting (“PRACTICALLY USABLE EMBODIMENTS”) encompass only equipment or methods for any one or more Excluded Lithography Technologies, and 

(ii) the Patent claim contains one or more limitations by reason of which the Practically Usable Embodiments of the Patent claim encompass only equipment
or methods for the Excluded Lithography Technology and that are material to the patentability of the Patent claim; 
 provided that: 

(A) actual use in a commercial setting is not required for an embodiment of a Patent claim to qualify as a Practically Usable Embodiment, 

(B) an embodiment of a Patent claim is not a Practically Usable Embodiment outside the Excluded Lithography Technology if it does not have practical
utility as an improvement upon, or alternative solution to, existing technology other than the Excluded Lithography Technology, 
 (C) no Patent
claim that covers actual and bona fide commercial Lithography Equipment or Lithography methods, anywhere in the world from any source, other than equipment or methods for an Excluded Lithography Technology, shall qualify as an Excluded Claim, and

 (D) if a dependent claim of a Patent depends from another claim of such Patent that does not qualify as an Excluded Claim, such dependent
claim shall not qualify as an Excluded Claim simply by virtue of the fact that it recites an Excluded Lithography Technology. 
 It is the
Parties’ intent to exclude only Patent claims in which the “heart of the invention” of such Patent claim is practically usable only in equipment or methods for an Excluded Lithography Technology. 

The Parties anticipate that, in preparing the Excluded Claims List, they may develop ideas for clarifying the Excluded Claim Criteria for whether certain
types of Patent claims should qualify as Excluded Claims. Accordingly, upon completion of the Excluded Claims List, the Parties will revisit and negotiate clarifications to such Excluded Claim Criteria in good faith, and if the Parties agree on any
such clarifications (each in its sole discretion), they will amend the Excluded Claim Criteria to implement such clarifications. 
 1.2.17
“SCHEDULE D PATENTS” means the Patents listed on Schedule D hereto. 
 1.2.18 “SCHEDULE D PATENT FAMILY” means, with respect
to a Schedule D Patent, collectively, such Schedule D Patent and (i) any Patents claiming priority from such Schedule D 

  

					
		  	9	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Patent, but excluding claims of such Patents that are not entitled to claim priority from such Schedule D Patent, and (ii) any Patents from which such Schedule D Patent claims priority, but
excluding claims of such Patents that are not supported by such Schedule D Patent. The excluded claims described in subclauses (i) and (ii) hereof, together with any Excluded Claims of any Schedule D Patent Family Member, are referred to
as “SCHEDULE D OMITTED CLAIMS”. For the avoidance of doubt, it is understood that there shall, subject to reduction pursuant to Section 2.8.3, be three Schedule D Patent Families, one based on each of the three Schedule D Patents.

 1.2.19 “SCHEDULE D PATENT FAMILY MEMBER” means, with respect to any Schedule D Patent Family, separately, each Patent in such
Schedule D Patent Family (excluding any Schedule D Omitted Claims thereof). 
 1.2.20 “EXCLUDED NIKON PATENTS” means issued Eligible
Nikon Patent Family Members that are designated by Nikon as set forth in Section 2.8.1. 
 1.2.21 “ELIGIBLE NIKON PATENT FAMILY”
means, with respect to a Designated Nikon Patent, collectively, such Designated Nikon Patent and (i) any Patents claiming priority from such Designated Nikon Patent, but excluding claims of such Patents that are not entitled to claim priority
from such Designated Nikon Patent, and (ii) any Patents from which such Designated Nikon Patent claims priority, but excluding claims of such Patents that are not supported by such Designated Nikon Patent. For the avoidance of doubt, it is
understood that there shall, subject to reduction pursuant to Section 2.8.3, be three Eligible Nikon Patent Families, one based on each of the three Designated Nikon Patents. 
 1.2.22 “ELIGIBLE NIKON PATENT FAMILY MEMBER” means, with respect to any Eligible Nikon Patent Family, separately, each Patent in such Eligible Nikon Patent Family. 

1.3 Additional Definitions Relating to Licensed Products. 
 1.3.1 “ASML LICENSED PRODUCTS” means Lithography Equipment and all applications therefor, but excluding Optical Components until the occurrence of a Licensed Product Expansion, at which time the
term “ASML Licensed Products” shall automatically be deemed to mean “Lithography Equipment and all applications therefor, including Optical Components” for all purposes hereunder, including the license grants in Section 2.1,
as more fully described in, and subject to the conditions set forth in, Section 2.10. For purposes of clarity, “ASML Licensed Products” shall in all events include ASML’s products within the following product families, as and in
the form marketed by ASML as of the Effective Date: TwinScan, PAS, MicraScan and Micralign series, including components thereof, as described in Section 1.3.5, other than Optical Components as long as they are not ASML Licensed Products
pursuant to this Section 1.3.1. 
 1.3.2 “LICENSED PRODUCT EXPANSION” shall have the meaning set forth in Section 2.10.

 1.3.3 “LICENSED PRODUCTS” means the ASML Licensed Products or the Nikon Licensed Products, as applicable. 

1.3.4 “LITHOGRAPHY” means exposing a resist using optical (photons) projection means (including extreme ultraviolet) or particle (including
electron beam) projection means. 

  

					
		  	10	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 1.3.5
“LITHOGRAPHY EQUIPMENT” means, individually and collectively, any tool or machine for transferring a pattern onto a substrate by Lithography, for use in the fabrication of integrated circuits, thin film heads, flat panel displays,
micromachines, and other applications with similar requirements (including (i) separately installed components of such tool or machine, (ii) any components integrated in such tool or machine, (iii) materials for use in, and solely to
the extent they are for use in, the operation of such tool or machine, such as fluids and gases, and (iv) any software used to operate or control such tool or machine), including where such tool or machine uses and/or incorporates masks, or
uses, incorporates and/or processes resists or substrates, including wafers, provided that “Lithography Equipment” shall not include masks, resists, or such substrates themselves. 
 1.3.6 “NIKON LICENSED PRODUCTS” means Lithography Equipment and all applications therefor, including Optical Components. For purposes of clarity, “Nikon Licensed Products” shall in all
events include Nikon’s products within the following product families, as and in the form marketed by Nikon as of the Effective Date: NSR series and FX series. 
 1.4 Interpretation. 
 1.4.1 Certain Terms. The words “hereof,”
“herein,” “herewith,” “hereunder” and similar words refer to this Agreement as a whole and not to any particular provision of this Agreement. The term “including” is not limited and means “including
without limitation.” 
 1.4.2 Section References; Titles and Subtitles. Unless otherwise noted, all references to Sections and
Schedules herein are to Sections and Schedules of this Agreement. The titles, captions and headings of this Agreement are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of
this Agreement. 
 1.4.3 Reference to Persons, Agreements, Statutes. Unless otherwise expressly provided herein, (a) references to a
Person include its successors and permitted assigns, (b) references to agreements (including this Agreement) and other contractual instruments shall be deemed to include all subsequent amendments, restatements and other modifications thereto or
supplements thereof and (c) references to any statute or regulation are to be construed as including all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such statute or regulation.

 1.4.4 Further Negotiations. Any reference in this Agreement to subsequent meetings, discussions, or negotiations between the Parties
shall be interpreted to include an obligation of the Parties to conduct such meetings, discussions, or negotiations in good faith. 
 2.
LICENSE GRANTS 
 2.1 Grant to ASML. Nikon on behalf of itself and its Subsidiaries, hereby grants to ASML and its Subsidiaries, under the
Nikon Licensed Patents, retroactive to the Effective Application Date of each Nikon Licensed Patent, a non-exclusive, non-sublicensable (provided that this restriction on sublicensing shall not limit or otherwise affect the immunities and additional
commitments set forth in Sections 3 and 4), non-transferable (except as set forth in Section 9.1) license to (a) make, use (including use with patterns or masks for processing substrates such as wafers), sell, offer to sell, import,
export, lease and otherwise convey ASML Licensed Products anywhere in the world, (b) have ASML Licensed Products made by their suppliers anywhere in the world, provided that such ASML Licensed Products (i) are made by such suppliers in
accordance with specifications provided by, or agreed upon with, ASML or any of its Subsidiaries, and (ii) are not “off the shelf” products offered for sale, lease, or other conveyance to Persons other than ASML or its Subsidiaries,
(c) practice any method or process anywhere in the world in connection with the design, manufacture, installation, assembly, operation, adjustment, measurement, 

  

					
		  	11	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
qualification, maintenance, support, repair, or diagnosis of ASML Licensed Products designed, made, used and/or sold under this Section 2.1, and (d) make, have made, and use any tool,
software, machine, or other apparatus anywhere in the world in connection with the design, manufacture, installation, assembly, operation, adjustment, measurement, qualification, maintenance, support, repair, or diagnosis of ASML Licensed Products
designed, made, used and/or sold under this Section 2.1. Notwithstanding the foregoing, to the extent that the licenses granted in this Section 2.1 include a sublicense under any third party rights, such sublicense shall not exceed in
scope the license granted to Nikon by the applicable third party licensor or the rights that Nikon is otherwise authorized to sublicense under any agreement with such third party licensor. 
 2.2 Grant to Nikon. ASML, on behalf of itself and its Subsidiaries, hereby grants to Nikon and its Subsidiaries, under the ASML Licensed Patents, retroactive to the Effective Application Date of each ASML
Licensed Patent, a non-exclusive, non-sublicensable (provided that this restriction on sublicensing shall not limit or otherwise affect the immunities and additional commitments set forth in Sections 3 and 4), non-transferable (except as set forth
in Section 9.1) license to (a) make, use (including use with patterns or masks for processing substrates such as wafers), sell, offer to sell, import, export, lease and otherwise convey Nikon Licensed Products anywhere in the world,
(b) have Nikon Licensed Products made by their suppliers anywhere in the world, provided that such Nikon Licensed Products (i) are made by such suppliers in accordance with specifications provided by, or agreed upon with, Nikon or any of
its Subsidiaries, and (ii) are not “off the shelf” products offered for sale, lease, or other conveyance to Persons other than Nikon and its Subsidiaries, (c) practice any method or process anywhere in the world in connection
with the design, manufacture, installation, assembly, operation, adjustment, measurement, qualification, maintenance, support, repair, or diagnosis of Nikon Licensed Products designed, made, used, and/or sold under this Section 2.2, and
(d) make, have made, and use any tool, software, machine, or other apparatus anywhere in the world in connection with the design, manufacture, installation, assembly, operation, adjustment, measurement, qualification, maintenance, support,
repair, or diagnosis of Nikon Licensed Products designed, made, used and/or sold under this Section 2.2. Notwithstanding the foregoing, to the extent that the licenses granted in this Section 2.2 include a sublicense under any third party
rights, such sublicense shall not exceed in scope the license granted to ASML by the applicable third party licensor or the rights that ASML is otherwise authorized to sublicense under any agreement with such third party licensor. 

2.3 Excluded Claims List. 
 2.3.1 Creation.
Within sixty (60) days of the Effective Date, the Parties will attempt to agree on a list of Patent claims for each Excluded Lithography Technology that will be excluded from the Licensed Patents (as so agreed or as finalized by the Designated
Neutral, the “EXCLUDED CLAIMS LIST”). The Excluded Claims List will only include Patent claims that are contained in Patents nominated by each Party as follows: for each Excluded Lithography Technology, each Party may nominate claims from
no more than five (5) English-language Patents, provided that for the purposes of the foregoing, a Patent and all of its counterparts and its continuation, divisional, and continuation-in-part applications will be counted as a single Patent. If
the Parties are unable to agree on the Excluded Claims List within sixty (60) days of the Effective Date, the Designated Neutral will have the authority to finalize the Excluded Claims List by including on the list all Patent claims nominated
by the Parties for each Excluded Lithography Technology (as described above) that qualify as Excluded Claims pursuant to Sections 1.2.15 and 1.2.16, and omitting from the Excluded Claims List all such Patent claims that do not qualify as Excluded
Claims pursuant to Sections 1.2.15 and 1.2.16. The Excluded Claims List, with the entries agreed to by the Parties, and, as applicable, finalized by the Designated Neutral, shall be incorporated into this Agreement as Schedule A. 

  

					
		  	12	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 2.3.2
Significance of Inclusion. Inclusion of a Patent claim on the Excluded Claims List will constitute a binding determination that such Patent claim is an Excluded Claim, unless and until such Patent claim ceases to meet the Excluded Claim Criteria
because of changed circumstances (such as, for example, the subsequent emergence or awareness of a practical use of an embodiment of such Patent claim in a commercial setting other than for an Excluded Lithography Technology). 

2.3.3 Significance of Non-Inclusion. For purposes of clarification: 
 (a) the Excluded Claims List will be deemed exemplary and will not constitute an exhaustive list of the Excluded Claims for any Excluded Lithography Technology nor will the failure to nominate a Patent
claim for the list be deemed an admission that the claim is not an Excluded Claim; and 
 (b) a Patent claim that does not appear on the
Excluded Claims List will be an Excluded Claim if (and for so long as) it qualifies as an Excluded Claim pursuant to Sections 1.2.15 and 1.2.16, whether or not such Patent claim was in existence at the time of the creation of the Excluded Claims
List. 
 2.3.4 Process for Removing Claims from Excluded Claims List. If a Party believes that a Patent claim, whether of such Party or of the
other Party, that is included in the Excluded Claims List has ceased to meet the Excluded Claim Criteria because of changed circumstances as described in Section 2.3.2, such Party shall notify the other Party in writing of such belief and,
subject to existing confidentiality obligations, the basis therefor. If the other Party agrees in writing that such Patent claim should no longer be included within the Excluded Patent Claims List, such Patent claim shall be deemed to be removed
from the Excluded Claims List for all purposes hereunder. If the other Party does not so agree within thirty (30) days after its receipt of such notice, the Parties shall, at the request of either Party, resolve the matter under the Arbitration
Agreement. 
 2.4 Inquiries as to Patents. In the event that a third party Sues a Party or its Subsidiary and alleges or asserts that such Party
has infringed, or invites such Party to license, any one or more issued Patents of such third party, or if a Party is otherwise actively engaged in licensing negotiations with a third party with respect to any one or more issued Patents (each a
“PATENT IN DISPUTE”), such Party may request that the other Party confirm whether each such Patent in Dispute is included within the Licensed Patents (whether as an Owned Patent, a Sublicensable Patent or a Licensable Co-Owned Patent) of
such other Party hereunder (a “LICENSE INQUIRY”). License Inquiries shall be in writing and shall set forth the identity of the applicable third party and each Patent in Dispute. With respect to each License Inquiry, the responding Party
will inform the inquiring Party (a) if the Patent in Dispute is a Licensed Patent of such responding Party, and (b) if so, the scope of the rights thereunder, if any, to grant and extend the licenses, immunities, and additional commitments
granted and extended hereunder. If, after responding to any License Inquiry, the responding Party becomes aware of any inaccuracy in the response to a License Inquiry provided to the other Party, the responding Party will, as its sole obligation or
liability for any such failure, promptly notify the other Party and provide a corrected response. 
 2.5 Conversion of Class B Patents To
Class A Patents. 
 2.5.1 At any time from the Effective Date until six (6) months after the end of the Agreement Term, each Party
shall have the right to designate up to five (5) Convertible Patents of the other Party to be converted into Class A Patents, in which case such designated Convertible Patents, together with all Patents anywhere in the world that issue
from or claim priority to either the application that issued as the designated Convertible Patent or any application or applications from which the 

  

					
		  	13	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
designated Convertible Patent claims priority, including all counterparts (including foreign counterpart Patents), divisionals, continuations, continuations-in-part, reissues and results of
re-examinations thereof (“RELATED PATENTS”), shall be deemed Class A Patents effective as of and retroactive to the Effective Application Date of such Convertible Patent (or, if earlier, the earliest Effective Application Date among
the Related Patents thereof) for all purposes of this Agreement (including the respective licenses and immunities). For the avoidance of doubt, such retroactive effect shall also apply with respect to Related Patents that issue after such
conversion. 
 2.5.2 Notwithstanding the period described in the first clause of Section 2.5.1, in the event a Party designates a
Convertible Patent of the other Party to be converted into a Class A Patent (the “INITIALLY DESIGNATED PATENT”) and the other Party is of the opinion that such Initially Designated Patent would, in whole or in part, not be a Licensed
Patent of such other Party if it were a Class A Patent (e.g., because such Patent is not Owned or Sublicensable or to the extent it includes Excluded Claims), then such other Party shall promptly notify such first Party thereof. If the Parties
agree that such Initially Designated Patent would not be a Licensed Patent of such other Party if it were a Class A Patent, then such first Party shall have the right, within six (6) months of such agreement, to designate another
Convertible Patent (the “SUBSEQUENTLY DESIGNATED PATENT”) to be converted into a Class A Patent in lieu of such Initially Designated Patent as to which Subsequently Designated Patent the Parties agree that it would be a Licensed
Patent of such other Party if it were a Class A Patent. If the Parties do not so agree with respect to the Initially Designated Patent or the Subsequently Designated Patent, they shall resolve such dispute pursuant to the Arbitration Agreement.
If it is determined in such arbitration that such Initially Designated Patent or Subsequently Designated Patent would not be a Licensed Patent of such other Party if it were a Class A Patent, then such first Party shall provide in such
arbitration proceedings a list, in order of preference, of Convertible Patents to be converted into a Class A Patent in lieu of such Initially Designated Patent or Subsequently Designated Patent and the first of such Patents, if any, with
respect to which it is determined in such arbitration proceedings that it would be a Licensed Patent of the other Party if it were a Class A Patent shall be finally converted into a Class A Patent pursuant to Section 2.5.1 in lieu of
such Initially Designated Patent or Subsequently Designated Patent. If no Convertible Patent on such list is determined to meet such requirements, such Party may not convert any Convertible Patent into a Class A Patent in lieu of such Initially
Designated Patent or Subsequently Designated Patent. 
 2.6 Pre-Issuance Damages. To the extent, if any, that under applicable law a Party has
or its Subsidiaries have a right to claim damages or seek other remedies with respect to activities of the other Party, its Subsidiaries, or its or their respective Covered Entities or third party suppliers making Licensed Products for such other
Party as permitted under Sections 2.1 or 2.2, as applicable, occurring prior to the issuance of a Patent with respect to such Patent, each Party hereby waives and agrees not to assert such rights under Patents issuing after the License Term and
having an Effective Application Date after December 31, 2002 and that would have been Licensed Patents of such Party had they issued prior to the end of the License Term, but only with respect to activities occurring prior to the end of the
License Term that would have been licensed or immune from suit under this Agreement if such Patent were a Licensed Patent, and only for the period ending upon the end of the License Term. 
 2.7 Restricted Patents. 
 2.7.1 Covenant Not to Sue. 

(a) Each Party covenants, to the extent not precluded by contractual obligations that exist as of the Effective Date, that it shall not, and shall cause
its Subsidiaries not to, and shall not grant consent to, or otherwise assist, encourage, or permit, any Co-Owner of any Restricted Patent to Sue the other Party or its Subsidiaries, or their respective third party suppliers making Licensed Products
or 

  

					
		  	14	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Optical Components (but, in the case of ASML being such other Party, only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical
Components are ASML Licensed Products following a Licensed Product Expansion) for such Party as permitted under Sections 2.1 or 2.2, as applicable, for direct or indirect infringement (including for inducement of infringement or contributory
infringement) of any Restricted Patent (excluding any Excluded Claims thereof) based on activities that would be covered by such Party’s license under Sections 2.1 or 2.2 or sublicense pursuant to and in accordance with the Nikon-Zeiss Patent
Cross-License Agreement, as and if applicable, if such Restricted Patent were a Licensed Patent of such covenanting Party. Such covenant shall last perpetually (i) with respect to Class A Patents, and (ii) under Restricted Patents
that are Class B Patents and Restricted Patents that would be Class C Patents if they were Owned by the covenanting Party, with respect to activities of the other Party occurring prior to the end of the License Term that would be covered by the
other Party’s license under Sections 2.1, 2.2, or 2.3, as applicable, if such Restricted Patents were Licensed Patents of the covenanting Party. 
 (b) Each Party covenants, to the extent not precluded by contractual obligations that exist as of the Effective Date, that Sections 3.1, 3.2, 3.3, 4.2, and 4.3 shall apply to Restricted Patents to the
same extent and in the same manner and the same time periods as if such Restricted Patents were Owned by such covenanting Party. 
 2.7.2
Consent to License. Subject to Section 2.7.3, each Party hereby grants its consent to a license to the other Party of the full scope of the licenses granted to such other Party under this Agreement under any Restricted Patent of such Party,
provided, however, that such grant does not result in any payment obligations by such first Party to any Co-Owner of such Restricted Patent, other than payments relating to prosecution or maintenance of Patents. 

2.7.3 No Obligation to Seek Consent. Notwithstanding anything to the contrary in this Agreement, neither Party shall have any obligation to seek or
obtain consent from any Co-Owner of any Restricted Patent with respect to a grant of any license or immunity under such Restricted Patent. 

2.7.4 No Circumvention. Neither Party nor its respective Subsidiaries shall make any sale, assignment, transfer, or other conveyance or transaction
(i) with respect to any Lithography Patent that is a Licensed Patent Owned by such Party that would result in such Licensed Patent becoming a Restricted Patent, and (ii), solely during the Transition Period, with respect to any Lithography
Patent that is a Class B Patent or a Class C Patent Owned by such Party that would result in such Lithography Patent becoming a Restricted Patent during the Transition Period. 
 2.8 Excluded Nikon Patents. 
 2.8.1 Designation. Nikon shall be entitled to designate, from time
to time and at any time, in a writing provided to ASML and Zeiss SMT, issued Eligible Nikon Patent Family Members to be included in the Excluded Nikon Patents, provided that (a) the total number of Excluded Nikon Patents shall not exceed, at
any time, the total number of issued Schedule D Patent Family Members, and (b) the number of Excluded Nikon Patents issued in any one country shall not exceed, at any time, the number of Schedule D Patent Family Members issued in the same
country, provided that, for purposes of the foregoing, the European Community and all of its member states shall collectively be deemed to constitute “one country.” Nikon shall be entitled to designate issued Eligible Nikon Patent Family
Members to be included within the Excluded Nikon Patents in accordance with the foregoing, but Nikon shall not be entitled to subsequently change any such designation. For purposes of clarity, (i) no Eligible Nikon Patent Family Member shall be
deemed to be an Excluded Nikon Patent unless and until such Patent is designated by Nikon as an Excluded Nikon Patent pursuant to and in accordance with this 

  

					
		  	15	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Section 2.8.1, and (ii) Nikon may pre-designate a Patent pursuant to the foregoing at any time, including, for example, Patent applications, provided that a Patent application shall not
constitute an Excluded Nikon Patent unless and until a Patent or Patents issue from such application, at which time each such pre-designated issued Patent shall, as designated or, if not otherwise designated, in the order of issuance, and subject to
the limitations set forth in subclauses (a) and (b) of this Section 2.8.1, constitute an Excluded Nikon Patent. 
 2.8.2 No
License. Subject to Section 2.8.3, nothing in this Agreement, nor the activities of the Parties under or in connection with this Agreement, including, without limitation, the sale of any Licensed Product, shall be construed to grant or
otherwise convey or provide any right, license, immunity, or other defense, whether directly, by implication, estoppel, or otherwise, under any Excluded Nikon Patents to ASML or its Subsidiaries or any third party acquiring Licensed Products or
other products from ASML or its Subsidiaries. 
 2.8.3 Schedule D Patents. 
 (a) When and if, and as long as, at least all claims other than Schedule D Omitted Claims of all Patents within any one Schedule D Patent Family either (a) become Owned or Sublicensable by ASML or
its Subsidiaries, such that they are included within the ASML Licensed Patents, and/or (b) expire or are invalidated or abandoned, such that they are permanently not enforceable, then Nikon or ASML (as determined pursuant to
Section 2.8.3(b) below) shall select one Eligible Nikon Patent Family (including all Eligible Nikon Patent Family Members therein), excluding any Excluded Claims of any such Patents, which (i) shall be deemed to be included within the
Nikon Licensed Patents, retroactive to the Effective Application Date of such Patents, for all purposes hereunder (including the licenses, immunities and additional commitments granted or extended hereunder), and (ii) shall not be deemed to be,
or designable as, Excluded Nikon Patents as long as at least all claims other than Schedule D Omitted Claims of all Patents within the corresponding Schedule D Patent and Schedule D Patent Family Members thereof remain (A) Owned or
Sublicensable by ASML or its Subsidiaries or (B) subject to all the licenses, immunities, and additional commitments granted and extended by ASML and its Subsidiaries hereunder. 
 (b) On the first occasion that the condition set forth in Section 2.8.3(a) above occurs with respect to any one Schedule D Patent Family, Nikon shall be entitled to select, and shall select, the
first Eligible Nikon Patent Family to be included in the Nikon Licensed Patents as set forth in Section 2.8.3(a). On the occasion that the condition set forth in Section 2.8.3(a) above occurs with respect to a second Schedule D Patent
Family, ASML shall be entitled to select, and shall select, the second Eligible Nikon Patent Family to be included in the Nikon Licensed Patents as set forth in Section 2.8.3(a). Each Party shall make the selection described in this
Section 2.8.3(b) in a writing provided to the other Party and Zeiss SMT no later than thirty (30) days following ASML’s notification to Nikon and Zeiss SMT that the condition set forth in Section 2.8.3(a) has occurred. On the
occasion that the condition set forth in Section 2.8.3(a) occurs with respect to the remaining Schedule D Patent Family, the remaining Eligible Nikon Patent Family shall automatically be included in the Nikon Licensed Patents as set forth in
Section 2.8.3(a). 
 (c) During the life of the Eligible Nikon Patent Family Members, except while such Patents are included in the Nikon
Licensed Patents as provided under this Section 2.8.3, in which case Section 9.3 shall apply, Nikon shall, and shall ensure that its Subsidiaries shall, maintain all rights under each of the Eligible Nikon Patent Family Members necessary
in order to grant to ASML and its Subsidiaries the full scope of the licenses and immunities granted under Nikon Licensed Patents hereunder should such Eligible Nikon Patent Family Members be included in the Nikon Licensed Patents. 

  

					
		  	16	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 2.8.4
Consequences of Assertion. If Nikon or any of its Subsidiaries Sues ASML, Zeiss SMT, their respective Subsidiaries, or any of their respective vendors or Covered Entities, for direct or indirect infringement (including inducement of infringement or
contributory infringement) of any Excluded Nikon Patent based on any activity that would be covered by a license or immunity under this Agreement if such Excluded Nikon Patent were included within the Nikon Licensed Patents, then ASML shall have the
right to terminate (a) at any time after the end of the Withdrawal Period (as defined below), if applicable, or (b) if no Withdrawal Period is applicable, at any time thereafter, all of the licenses, immunities, and other commitments
granted and extended by ASML and its Subsidiaries to Nikon and its Subsidiaries and their respective Covered Entities, vendors, and Glass Suppliers under this Agreement (a “FULL RIGHTS TERMINATION”) upon written notice to Nikon, provided,
however, that ASML shall have no right to initiate or effect such Full Rights Termination (i) in the cases expressly set forth in Section 2.8.5, or (ii) if Nikon or its Subsidiary notifies ASML in writing of the existence of such Suit
and together with such notice provides to ASML copies of the initial court filing made by Nikon or its Subsidiary in connection with such Suit within thirty (30) days of the filing of any legal action, and Nikon or its Subsidiary takes, within
two (2) months after Nikon’s or its Subsidiary’s receipt of a written response by ASML to such notice stating ASML’s good faith belief that such Suit is within the scope of this Section 2.8.4 and the reasons therefor (the
“WITHDRAWAL PERIOD”), all actions required on its part to withdraw such Suit completely. Such Full Rights Termination shall have no effect on the licenses, immunities and other commitments granted or extended to ASML, its Subsidiaries,
Covered Entities, vendors and Glass Suppliers by Nikon and its Subsidiaries as set forth in this Agreement. 
 2.8.5 Defensive Assertion.

 (a) No Termination for Nikon Defensive Suits. In the event that the Specified Entity or any of its Affiliates Sues Nikon or any of its
Subsidiaries under any Schedule D Patent Family Member (a “SPECIFIED ENTITY SUIT”), then, subject to this Section 2.8.5, Nikon and its Subsidiaries shall be permitted to Sue the Specified Entity or such Affiliate (a “NIKON
DEFENSIVE SUIT”). The Nikon Defensive Suit shall be under an aggregate number of Excluded Nikon Patents that does not exceed the aggregate number of issued Schedule D Patent Family Members that are asserted by the Specified Entity and its
Affiliates in the Specified Entity Suit. Section 2.8.4 shall not apply with respect to such Nikon Defensive Suit, and ASML shall have no right to initiate or effect a Full Rights Termination on account of such Nikon Defensive Suit. 

(b) Excess Assertion By Nikon. If Nikon asserts against the Specified Entity and/or its Affiliates in a Nikon Defensive Suit an aggregate number of
Excluded Nikon Patents greater than the aggregate number of issued Schedule D Patent Family Members asserted by the Specified Entity and/or its Affiliates against Nikon and/or its Subsidiaries in such action (an “EXCESS ASSERTION”), then,
if Nikon and/or its Subsidiaries fail to take all actions required on their part to withdraw their claims completely under such number of Excluded Nikon Patents as is required to eliminate the Excess Assertion within thirty (30) days from such
Excess Assertion, ASML may, at its sole discretion upon written notice to Nikon and Zeiss SMT, designate any of the Excluded Nikon Patents asserted in such Nikon Defensive Suit as Nikon Licensed Patents, up to a number of Excluded Nikon Patents as
required to eliminate the Excess Assertion, and any Excluded Nikon Patents that are so designated shall be deemed ab initio to be Nikon Licensed Patents for all purposes of this Agreement, including for purposes of the immunities and other
commitments granted or extended by Nikon and its Subsidiaries under Sections 2.9, 3, and 4. In no event shall ASML be entitled to initiate or effect a Full Rights Termination on account of any Excess Assertion. 

(c) Specified Entity Assertion of Schedule D Omitted Claims. The Parties acknowledge that, because Schedule D Patent Family Members do not include
Schedule D Omitted Claims, a Suit by the Specified Entity or its Affiliates in which only Schedule D Omitted Claims are 

  

					
		  	17	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
asserted does not constitute a Specified Entity Suit hereunder, and does not give rise to Nikon’s or its Subsidiaries’ right to bring a Nikon Defensive Suit pursuant to
Section 2.8.5(a). The Parties further acknowledge that it may be difficult to determine whether a Patent claim asserted in a Suit by the Specified Entity and/or its Affiliates is a Schedule D Omitted Claim. Accordingly, if the Specified Entity
and/or its Affiliates assert any claim of any Schedule D Patent and/or any Patent claiming priority from a Schedule D Patent and/or any Patent from which a Schedule D Patent claims priority against Nikon and/or its Subsidiaries (a “SCHEDULE D
SUIT”), and Nikon and/or its Subsidiaries subsequently Sue the Specified Entity and/or its Affiliates under Excluded Nikon Patents (a “SCHEDULE D RESPONSE”), such Schedule D Response by Nikon and/or its Subsidiaries shall not be
grounds for a Full Rights Termination pursuant to Section 2.8.4. Instead, (A) if a Party believes that the Schedule D Suit is partly or solely based on Schedule D Omitted Claims, such Party shall notify the other Party of such belief, and
if the Parties disagree as to whether such Schedule D Suit is partly or solely based on Schedule D Omitted Claims, the Parties shall resolve such dispute under the Arbitration Agreement including, if applicable, which of the Patent claims asserted
in such Schedule D Suit are Schedule D Omitted Claims, and (B) if it is determined in such arbitration procedure that all or some of the Patent claims asserted in the Schedule D Suit are Schedule D Omitted Claims, the consequences shall be as
set forth in the following subclauses (i) and (ii) of this Section 2.8.5. 
 (d) If (A) it is determined in such arbitration
that all Patent claims asserted by the Specified Entity or its Affiliates in such Schedule D Suit against Nikon or its Subsidiaries are Schedule D Omitted Claims, and (B) Nikon and its Subsidiaries fail to withdraw completely all Suits which
assert any Excluded Nikon Patents against the Specified Entity and/or its Affiliates within thirty (30) days after such determination, then all Nikon Excluded Patents asserted by Nikon and/or its Subsidiaries in such Suit shall be deemed ab
initio to be Nikon Licensed Patents for all purposes of this Agreement, including for purposes of the licenses granted to ASML and its Subsidiaries under Section 2.1 and the immunities and other commitments granted or extended by Nikon and its
Subsidiaries under Sections 2.9, 3, and 4. In no event shall ASML be entitled to initiate or effect a Full Rights Termination on account of any such Suit and/or failure to withdraw. 
 (ii) If it is determined in such arbitration procedure that some but not all Patent claims asserted by the Specified Entity and/or its Affiliates in the Specified Entity Action are Schedule D Omitted
Claims, then Section 2.8.5(a) or 2.8.5(b), as applicable, shall apply, it being understood that, if the Specified Entity and/or its Affiliates asserted any claim of a Schedule D Patent Family Member other than a claim that has been determined
in an arbitration procedure pursuant to this Section 2.8.5(c), or agreed by the Parties in writing, to be a Schedule D Omitted Claim, such Schedule D Patent Family Member shall be counted as a Schedule D Patent Family Member asserted by the
Specified Entity and/or its Affiliates for purposes of determining the number of Nikon Excluded Patents that may be asserted in any Nikon Defensive Suit in accordance with Section 2.8.5(a). 

2.9 Transition Period Covenants and Limitation of Remedies. 
 2.9.1 Covenant Not To Sue During Transition Period. Each Party covenants that, during the Transition Period, it shall not, and shall cause its Subsidiaries not to (such Party and its Subsidiaries being
referred to as the “NON-ASSERTING PARTY”), Sue the other Party or its Subsidiaries, or their respective third party suppliers making Licensed Products or Optical Components (but, in the case of ASML being such other Party, only as long as
ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product Expansion) for such Party as permitted under Sections 2.1 or 2.2, as
applicable (as applicable, the “DEFENDANT PARTY”), for direct or indirect infringement (including for inducement of infringement or contributory infringement) of any (i) Class B Patents that were Licensed Patents of the Non-Asserting
Party prior to the end of the License Term, (ii) Class C 

  

					
		  	18	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Patents Owned or Sublicensable by the Non-Asserting Party, or (iii), to the extent not precluded by contractual obligations that exist as of the Effective Date, Restricted Patents of the
Non-Asserting Party, excluding, in each case, any Excluded Claims thereof and, in each case, based on (a) the Defendant Party’s activities that would be covered by the Defendant Party’s license under Sections 2.1 or 2.2, as
applicable, or sublicense pursuant to and in accordance with the Nikon-Zeiss Patent Cross-License Agreement, if such Class B Patents, Class C Patents, or Restricted Patents were Licensed Patents (collectively “LITHOGRAPHY ACTIVITIES”), but
solely with respect to Lithography Activities that occur during the Transition Period, or (b) activities of Covered Entities of the Defendant Party to the extent such activities are within the scope of the immunities granted by the
Non-Asserting Party under this Agreement. 
 2.9.2 Limitation of Remedies As To Transition Period. Nothing in Section 2.7 or in this
Section 2.9 shall constitute any restriction or limitation on the Non-Asserting Party’s right and ability (a) to Sue the Defendant Party at any time after the Transition Period, or (b) to seek, after the Transition Period, any
remedies with respect to any activities occurring during the Transition Period (including, without limitation, Lithography Activities), provided, however, that with respect to Lithography Activities occurring during the Transition Period, and only
to the extent such Lithography Activities occur during the Transition Period, such remedies shall be limited to damages in the form of a reasonable royalty not to exceed three percent (3%) of the Net Selling Price of the applicable Licensed
Products or Optical Components. 
 2.9.3 No Other Rights. Nothing in this Section 2.9 shall be construed to grant or otherwise convey or
provide any right or license under any Patents, whether directly, by implication, estoppel, or otherwise. Nothing in this Section 2.9, nor the Parties’ or their Subsidiaries’ conduct pursuant hereto, shall give rise to any defense,
claim, or counterclaim, including based on laches or equitable estoppel, based on the failure of a Party or its Subsidiaries to bring Suit or otherwise assert a claim during the Transition Period where such Party or its Subsidiaries could not have
brought such Suit or assert such claim in accordance with this Section 2.9, and the Defendant Party hereby expressly waives any such defense, claim, or counterclaim. 
 2.10 Licensed Product Expansion. If Zeiss SMT or any third party files for Zeiss SMT’s insolvency and such insolvency proceedings are opened by a court of competent jurisdiction or are not opened for
lack of assets (Nichteroffnung des Insolvenzverfahrens mangels Masse), or if Zeiss SMT is the subject of a bankruptcy or is dissolved, liquidated or ceases to do business in the ordinary course and, as a consequence of any of the foregoing, ASML
loses (and does not retain through a successor to Zeiss SMT or its rights, by operation of law, or otherwise) any rights under Nikon Licensed Patents that were sublicensed to ASML from Zeiss SMT pursuant to the Nikon-Zeiss Patent Cross-License
Agreement, then the term “ASML Licensed Products” shall automatically be deemed to mean “Lithography Equipment and all applications therefor, including Optical Components” for all purposes hereunder, including the license grants
in Section 2.1 and the immunities and other commitments extended by Nikon and its Subsidiaries under this Agreement (the “LICENSED PRODUCT EXPANSION”); provided, however, that (i) as a condition of such modification to the term
“ASML Licensed Products”, ASML shall assume responsibility to pay any of the Zeiss SMT Payments that Zeiss SMT has not paid to Nikon at the time of such modification, which amount(s) ASML shall pay within thirty (30) days following
the later of the due date therefor or Nikon’s notice to ASML thereof, and (ii) the scope of ASML’s rights under this Agreement with respect to Optical Components shall not exceed the scope of a permissible sublicense to ASML under the
Nikon-Zeiss Patent-Cross License Agreement, as it exists as of the Effective Date, as described therein. 

  

					
		  	19	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 3. CERTAIN
IMMUNITIES 
 3.1 Immunity for ASML Products. 
 3.1.1 The rights granted to ASML and its Subsidiaries in Section 2.1 shall include immunity as set forth in this Section 3.1 under the Nikon Licensed Patents and the Class C Patents Owned or
Sublicensable by Nikon or its Subsidiaries for the Covered Entities of ASML and its Subsidiaries for such Covered Entities’ use, importation, offer for sale, sale, lease, and other distribution or conveyance of ASML Licensed Products or Optical
Components (but only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product Expansion) made, had made, sold, offered for
sale, leased, imported or otherwise conveyed by or for ASML or its Subsidiaries pursuant to the license granted in Section 2.1. Such immunity means that Nikon shall not, and shall cause its Subsidiaries not to, Sue any Covered Entity of ASML or
its Subsidiaries for direct or indirect infringement (including for inducement of infringement or contributory infringement) based on such Covered Entities’ use, importation, offer for sale, sale, lease, and other distribution or conveyance of
such ASML Licensed Product or Optical Components (but only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product
Expansion) (a) at any time under any Class A Patents that are Nikon Licensed Patents, regardless of when such ASML Licensed Product or such Optical Component was first sold, leased, or otherwise distributed or conveyed by ASML or its
Subsidiaries, (b) at any time under Class B Patents that are at any time Nikon Licensed Patents, with respect to ASML Licensed Products or such Optical Components that were first sold, leased, or otherwise distributed or conveyed by ASML or its
Subsidiaries prior to or during the License Term or the Transition Period, and (c) at any time under Class C Patents enforceable by Nikon or its Subsidiaries, with respect to ASML Licensed Products or such Optical Components that were first
sold, leased, or otherwise distributed or conveyed by ASML or its Subsidiaries prior to or during the License Term or the Transition Period. 

3.1.2 Notwithstanding anything to the contrary in this Agreement, the immunity described in subclauses (b) and (c) of Section 3.1.1 is
expressly conditioned upon the applicable Covered Entity not Suing Nikon or any of its Subsidiaries for Patent infringement with respect to Lithography Equipment or any activities relating thereto (including the manufacture, use, sale, offer for
sale, or import of Lithography Equipment and any other activities described in Section 2.2 hereof), and upon any such Suit such immunity shall retroactively be null and void and of no effect with respect to such Covered Entity, and Nikon and
its Subsidiaries shall be entitled to seek any remedies against such Covered Entity available under applicable Law, including with respect to past activities, but only if Nikon has notified ASML of the existence of such Suit and the Covered Entity
has not taken all actions required on its part to withdraw such Suit completely within two (2) months after such notification. No Suit by Nikon or its Subsidiaries against such Covered Entity prior to any such withdrawal shall constitute a
breach of this Section 3.1 by Nikon or its Subsidiaries as long as Nikon or its Subsidiaries take all actions required on their part to withdraw such Suit completely within two (2) months after the Covered Entity has taken all actions
required on its part to withdraw its Suit completely. 
 3.2 Immunity for Nikon Products. 

3.2.1 The rights granted to Nikon and its Subsidiaries in Section 2.2 shall include immunity as set forth herein under the ASML Licensed Patents and
the Class C Patents Owned or Sublicensable by ASML or its Subsidiaries for the Covered Entities of Nikon and its Subsidiaries for such Covered Entities’ use, importation, offer for sale, sale, lease, and other distribution or conveyance of
Nikon Licensed Products made, had made, sold, offered for sale, leased, imported or otherwise conveyed by or for Nikon or its Subsidiaries pursuant to the license granted in Section 2.2. Such immunity means

  

					
		  	20	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
that ASML shall not, and shall cause its Subsidiaries not to, Sue any Covered Entity of Nikon or its Subsidiaries for direct or indirect infringement (including for inducement of infringement or
contributory infringement) based on such Covered Entities’ use, importation, offer for sale, sale, lease, and other distribution or conveyance of such Nikon Licensed Product (a) at any time under any Class A Patents that are ASML
Licensed Patents, regardless of when such Nikon Licensed Product was first sold, leased, or otherwise distributed or conveyed by Nikon or its Subsidiaries, (b) at any time under Class B Patents that are at any time ASML Licensed Patents with
respect to Nikon Licensed Products that were first sold, leased, or otherwise distributed or conveyed by Nikon or its Subsidiaries prior to or during the License Term or the Transition Period, and (c) at any time under Class C Patents
enforceable by ASML or its Subsidiaries, with respect to Nikon Licensed Products that were first sold, leased, or otherwise distributed or conveyed by Nikon or its Subsidiaries prior to or during the License Term or the Transition Period.

 3.2.2 Notwithstanding anything to the contrary in this Agreement, the immunity described in subclauses (b) and (c) of
Section 3.2.1 is expressly conditioned upon the applicable Covered Entity not Suing ASML or any of its Subsidiaries for Patent infringement with respect to Lithography Equipment or any activities relating thereto (including the manufacture,
use, sale, offer for sale, or import of Lithography Equipment and any other activities described in Section 2.1 hereof), and upon any such Suit such immunity shall retroactively be null and void and of no effect with respect to such Covered
Entity, and ASML, and its Subsidiaries shall be entitled to seek any remedies available against such Covered Entity under applicable Law, including with respect to past activities, but only if ASML has notified Nikon of the existence of such Suit
and the Covered Entity has not taken all actions required on its part to withdraw such Suit completely within two (2) months after such notification. No Suit by ASML or its Subsidiaries against such Covered Entity prior to any such withdrawal
shall constitute a breach of this Section 3.2 by ASML or its Subsidiaries as long as ASML or its Subsidiaries take all actions required on their part to withdraw such Suit completely within two (2) months after the Covered Entity has taken
all actions required on its part to withdraw its Suit completely. 
 3.3 Excluded Glass Products Claims. 

3.3.1 Neither Party will Sue the other Party or its Subsidiaries, or any of its or their respective Covered Entities, for direct or indirect infringement
(including for inducement of infringement or contributory infringement) based on such Party’s or its Subsidiaries’, or any of their respective Covered Entities’ use, importation, offer for sale, sale, lease, and other distribution or
conveyance of Licensed Products of the other Party or any Optical Components (but, if ASML is such other Party, only as long as ASML has a sublicense from Zeiss SMT under Section 2.2 of the Nikon-Zeiss Patent Cross-License Agreement, unless
Optical Components are ASML Licensed Products following a Licensed Product Expansion) sold as, installed in, or as replacement or upgrade components for, such Licensed Products, (i) at any time under any Excluded Claims described in
Section 1.2.15(c) that would have constituted Class A Patents and Licensed Patents of such first Party but for the application of Section 1.2.15(c), regardless of when such Licensed Products or such Optical Components were first sold,
leased, or otherwise distributed or conveyed by the other Party or its Subsidiaries, (ii) with respect to Licensed Products or such Optical Components that were first sold, leased, or otherwise distributed or conveyed by the other Party or its
Subsidiaries prior to or during the License Term or the Transition Period, at any time under any Excluded Claims described in Section 1.2.15(c) that would have constituted Class B Patents and Licensed Patents of such first Party but for the
application of Section 1.2.15(c), and (iii) with respect to Licensed Products or such Optical Components that were first sold, leased, or otherwise distributed or conveyed by the other Party or its Subsidiaries prior to or during the
License Term or the Transition Period, at any time under any claims of Patents having an Effective Application Date after December 31, 2002 and issuing during the Transition Period that are Excluded Claims described in Section 1.2.15(c)
and that would have constituted Licensed Patents of such Party but for the application of Section 1.2.15(c) had such Patents issued during the License Term (the claims described in 

  

					
		  	21	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
(ii) and (iii) of the foregoing being “TRANSITION PERIOD CLAIMS”). For the avoidance of doubt, the foregoing sentence shall not apply to Glass Suppliers of the other Party or its
Subsidiaries. 3.3.2 Notwithstanding anything to the contrary in this Agreement, the immunity pursuant to Section 3.3.1 under Transition Period Claims is expressly conditioned upon the applicable Covered Entity not Suing the applicable Party or
any of its Subsidiaries for Patent infringement, and upon any such Suit such immunity shall retroactively be null and void and of no effect with respect to such Covered Entity and the applicable Party and its Subsidiaries shall be entitled to seek
any remedies available, including with respect to past activities, but only if such Party has notified the other Party of the existence of such Suit and the Covered Entity has not taken all actions required on its part to withdraw such Suit
completely within two (2) months after such notification. No Suit by such Party or its Subsidiaries of such Covered Entity prior to any such withdrawal shall constitute a breach of this Section 3.3 by such Party or its Subsidiaries as long
as such Party or its Subsidiaries take all actions required on their part to withdraw such Suit completely within two (2) months after the Covered Entity has taken all actions required on its part to withdraw its Suit completely. 

4. ADDITIONAL COMMITMENTS 
 4.1
Opposition Proceedings. Neither Party (“OPPOSING PARTY”) nor its Subsidiaries will present arguments, or request, encourage or assist any designee, agent, or nominee or other strawman to present arguments, in any opposition proceedings
(which, for clarity, include reexaminations but do not include interference proceedings) (i) directed against any claim of any Class A Patent of the other Party or any of its Subsidiaries, to the extent that such claim only covers subject
matter that falls within the definition of the Licensed Products of the Opposing Party, or (ii) to the extent that the other Party covenants to the Opposing Party, in a form binding on the other Party and its Subsidiaries and assigns, that it
will never contend against the Opposing Party or its Subsidiaries or their respective vendors, direct and indirect resellers, distributors, users and other customers that such claim covers subject matter that falls outside the definition of the
Licensed Products of the Opposing Party. Each Party shall have the right, but not the obligation, at any time to provide the other Party with written notice identifying Subsidiaries of such Party. If an Opposing Party presents arguments, or
requests, encourages or assists any designee, agent, or nominee or other strawman to present arguments, in any opposition proceeding against a Subsidiary of the other Party that does not do business under a name including the name of the other Party
and has not previously been identified in writing to the Opposing Party, or that the Opposing Party does not actually know to be a Subsidiary of the other Party, then such presentation, request, encouragement or assistance shall not be deemed to be
a breach of this Section 4.1, provided that, upon receipt of written notice from the other Party of such Subsidiary relationship, such Opposing Party shall promptly withdraw from such opposition proceeding. 

4.2 Glass Product Suppliers 
 4.2.1 No
Injunction. Subject to Section 4.2.4, a Party and its Subsidiaries (collectively the “ASSERTING PARTY”) will not seek or obtain an injunction, restraint or other form of prohibitive order enjoining the supply of Excluded Glass
Products to the other Party or its Subsidiaries on the basis that such Excluded Glass Products infringe, directly or indirectly, the Patents of the Asserting Party. Subject to Section 4.2.4, the foregoing covenant and the provisions of
Section 4.2.2 shall last (i) perpetually under Class A Patents of the Asserting Party, and (ii) until the end of the Agreement Term under Class B Patents of the Asserting Party and under any patents that would have constituted
Class C Patents of the Asserting Party but for the application of Section 1.2.15(c) (each such period, as applicable, the “GLASS RESTRICTION PERIOD”). 
 4.2.2 Payment of Glass Excess Payment. 

  

					
		  	22	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 (a) If, during
the applicable Glass Restriction Period the Asserting Party asserts or seeks to assert any applicable Patents against a third party with respect to the supply of Excluded Glass Products by such third party (a “GLASS SUPPLIER”) to the other
Party (the “PURCHASING PARTY”), then, with regard to all Covered Excluded Glass Products, the Asserting Party shall pay any Glass Excess Payment to the Purchasing Party as set forth in Section 4.2.3. 

(b) For purposes of this Section 4.2: 

(i) “COVERED EXCLUDED GLASS PRODUCTS” means Excluded Glass Products that are (A) covered by a license under the Asserting Party’s
Patents, or (B) the subject of a damages award for infringement of the Asserting Party’s Patents. 
 (ii) “GLASS EXCESS
PAYMENT” means the portion of Attributable Glass Proceeds, if any, that exceeds an amount equal to [***] percent ([***]%) of the Purchasing Party’s Glass Product Expenses in any calendar year. By way of example,
if the Attributable Glass Proceeds in any calendar year are $[***] and the Glass Product Expenses for such calendar year are $[***], then the Glass Excess Payment payable by the Asserting Party to the other Party in
respect of such calendar year shall be such portion of $[***] that exceeds [***]% of $[***] ($[***]), i.e., $[***] in total. In no event shall the Purchasing Party be required to
pay any amount to the Asserting Party under this Section 4.2, even if in any calendar year the Attributable Glass Proceeds are less than [***] percent ([***]%) of the Purchasing Party’s Glass Product Expenses.

 (iii) “GLASS PRODUCT EXPENSES” means the aggregate amount paid by the Purchasing Party and its Subsidiaries to the Glass Supplier
for Covered Excluded Glass Products purchased by the Purchasing Party from the Glass Supplier in the applicable calendar year. 
 (iv)
“ATTRIBUTABLE GLASS PROCEEDS” means the sum of the following received with respect to any one calendar year: (A) Running Royalty Payments based on sales of Covered Excluded Glass Products to the Purchasing Party in such calendar year,
(B) Allocable Amortized Lump-Sum Payments allocable to such calendar year, and (C) Allocable Damages that are attributable to sales of Covered Excluded Glass Products to the Purchasing Party in such calendar year. 

(v) “RUNNING ROYALTY PAYMENTS” means running royalty payments made by the Glass Supplier to the Asserting Party under an applicable license
agreement the amounts of which are based on sales by the Glass Supplier of Covered Excluded Glass Products in any calendar year. “Running Royalty Payments” excludes any other payments, such as, for example, up-front license fees, annual
license fees, or other lump sum payments or payments other than variable payments based on sales of Covered Excluded Glass Products. 
 (vi)
“LUMP-SUM PAYMENTS” means up-front or lump-sum license fees paid by the Glass Supplier to the Asserting Party (e.g., annual license fees, but excluding, in any event, Running Royalty Payments) in consideration of, and to the extent
reasonably attributable to, the grant of license rights by the Asserting Party to the Glass Supplier, under the Asserting Party’s Patents covering Covered Excluded Glass Products, to make and sell Covered Excluded Glass Products. For the
avoidance of doubt, 

  

					
		  	23	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
if, under the applicable license agreement, the Asserting Party grants any rights, or provides any consideration, other than only the right to manufacture and sell Covered Excluded Glass
Products, only such portion of any up-front or recurring lump-sum license fees shall be taken into account, for purposes of calculating Lump-Sum Payments, that is reasonably attributable to the grant of the right to manufacture and sell Covered
Excluded Glass Products (but not any portion of such license fees that is reasonably attributable to other rights granted, or other consideration provided, to the Glass Supplier under such license agreement). 

(vii) “ALLOCABLE DAMAGES” means the positive difference, if any, between (A) such portion, if any, of damages finally assessed against the
Glass Supplier, and paid (including by way of setoff) to the Asserting Party, for infringement of the Asserting Party’s Patents based on the Glass Supplier’s sale of Covered Excluded Glass Products that is attributable to sales of Covered
Excluded Glass Products by the Glass Supplier to the Purchasing Party; the ratio of such portion to the total damages finally assessed against the Glass Supplier, and paid (including by way of setoff) to the Asserting Party, for infringement of the
Asserting Party’s Patents based on the Glass Supplier’s sale of Covered Excluded Glass Products being referred to as the “FRACTION”, minus (B) the Fraction multiplied by the amount of damages, if any, finally assessed
against the Asserting Party in the same lawsuit, cause, or action, or in a lawsuit pending at the same time, and paid (including by way of setoff) to the Glass Supplier, for infringement of the Glass Supplier’s Patents based on the Asserting
Party’s sales of Excluded Glass Products. 
 (viii) “AMORTIZED LUMP-SUM PAYMENTS” means the applicable portion of Lump-Sum
Payments when such Lump-Sum Payments are amortized on a straight line basis over the applicable Amortization Period. 
 (ix) “AMORTIZATION
PERIOD” means, (A) with respect to up-front license fees, the shorter of (I) a period of six (6) years from the payment date of such up-front license fee, or (II) the initial term of the applicable license agreement, and
(B) with respect to any recurring lump-sum license fees, the applicable period for which such recurring lump-sum license fee is made under the applicable license agreement (e.g., one year in case of an annual license fee). 

(c) “ALLOCABLE AMORTIZED LUMP-SUM PAYMENTS” means such portion of the Amortized Lump-Sum Payment, if any, that is attributable to sales of
Covered Excluded Glass Products by the Glass Supplier to the Purchasing Party in the applicable calendar year. 
 (d) For purposes of
clarification, nothing in this Section 4.2 or any other provision of this Agreement shall constitute, or shall be deemed to constitute, a restriction on the amount of any payments that may be sought by or payable to the Asserting Party or any
of its Subsidiaries from a Glass Supplier, whether on account of Excluded Glass Products supplied to the Purchasing Party or otherwise. 
 4.2.3
Payments and Records. The payments, if any, owed to the Purchasing Party pursuant to Section 4.2.2 by the Asserting Party shall be made annually within ninety (90) days following the last day of each calendar year of the Agreement Term.
The Parties agree to keep full and accurate books and records setting forth in reasonable detail the Attributable Glass Proceeds, the Glass Product Expenses, and the calculation of the Glass Excess Payment. The Purchasing Party shall report its
Glass Product Expenses, if any, to the Asserting Party no later than thirty (30) days following the last day 

  

					
		  	24	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
of each calendar year of the Agreement Term. In the event that the Asserting Party receives in any one calendar year (the “CURRENT YEAR”) any Attributable Glass Proceeds based on sales
in, or otherwise attributable or allocable to, any previous calendar year(s) ( “PREVIOUS YEAR(S)”), the Asserting Party will notify the Purchasing Party thereof within thirty (30) days following the last day of such Current Year and
the Purchasing Party may then, unless previously reported, report its Glass Product Expenses for such Previous Year(s) to the Asserting Party within ninety (90) days following the last day of such Current Year. The Asserting Party will then
calculate or recalculate the Glass Excess Payment, if any, for such Previous Year(s) and submit its report relating thereto within one hundred twenty (120) days following the last day of the Current Year, together with the payment of any Glass
Excess Payment owed and not previously paid for such Previous Year(s). 
 4.2.4 Defensive Actions. The provisions of Sections 4.2.1 through
4.2.3 will be suspended, and during such suspension shall cease to bind the Asserting Party with respect to (but only with respect to) any Glass Supplier or any of its Subsidiaries if such Glass Supplier or any of its Subsidiaries seeks an
injunction, restraint or other form of prohibitive order from any Government Authority against the Asserting Party on the basis that the Asserting Party or any of its products or services allegedly infringes, directly or indirectly, the Patents of
such Glass Supplier (“GLASS PROCEEDINGS”) prior to any Suit by the Asserting Party against such Glass Supplier. Such suspension shall last as long as such Glass Proceedings are not Finally Resolved. Upon Final Resolution of such Glass
Proceedings, the provisions of Sections 4.2.1 through 4.2.3 shall (i) be again effective from and after such Final Resolution, if such Glass Proceedings are Finally Resolved by either an amicable settlement between the Asserting Party and the
Glass Supplier or a withdrawal of all such Glass Proceedings by the Glass Supplier, and (ii) terminate and permanently cease to bind the Asserting Party with respect to such Glass Supplier in all other cases. Upon termination or during any
suspension of the provisions of Sections 4.2.1 through 4.2.3 the Asserting Party shall be entitled to seek any remedies available, including with respect to past activities. 
 4.3 Special Mask Technology 
 4.3.1 Definitions. For purposes of this Section 4.3:

 (a) “EXCLUDED SPECIAL MASK CLAIM” means an Excluded Claim that is described in Section 1.2.14(d); 

(b) “CLASS A EXCLUDED SPECIAL MASK CLAIM” means an Excluded Special Mask Claim that would have been included in a Class A Patent within
the Licensed Patents of a Party or its Subsidiaries (collectively, the “LICENSOR PARTY”) but for the application of Section 1.2.14(d). 
 (c) “CLASS B EXCLUDED SPECIAL MASK CLAIM” means an Excluded Special Mask Claim that would have been included in a Class B Patent within the Licensed Patents of a Licensor Party but for the
application of Section 1.2.14(d). 
 (d) “CLASS C EXCLUDED SPECIAL MASK CLAIM” means an Excluded Special Mask Claim that is
included in a Patent Owned or Sublicensable by a Licensor Party having an Effective Application Date after December 31, 2002 and issuing during the Transition Period. 

  

					
		  	25	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 4.3.2 Limited
Party Immunity. The Licensor Party will not Sue the other Party or its Subsidiaries (collectively, the “OTHER PARTY”) at any time, during or after the Agreement Term: 
 (a) for direct or indirect infringement (including contributory infringement and inducement to infringe) of any Class A Excluded Special Mask Claim based on (i) activities of the Other Party
occurring at any time before, during or after the Agreement Term that would be covered by the Other Party’s license under Sections 2.1 or 2.2, as applicable, if such Class A Excluded Special Mask Claim were a licensed claim within a
Licensed Patent, or (ii) a Covered Entity’s use, import, repair, offer for sale, sale, lease, and other distribution or conveyance at any time before, during or after the Agreement Term of Licensed Products or Optical Components (but, if
ASML is such Other Party, only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product Expansion) that were first sold,
leased, or otherwise distributed or conveyed by the Other Party at any time before, during or after the Agreement Term and the sale, lease, or other distribution or conveyance of which by the Other Party would be covered by the Other Party’s or
its Subsidiaries’ license under Sections 2.1 or 2.2, as applicable, if such Class A Excluded Special Mask Claim were a licensed claim within a Licensed Patent. 
 (b) for direct or indirect infringement (including contributory infringement and inducement to infringe) of any Class B Excluded Special Mask Claim or Class C Excluded Special Mask Claim based on either
(i) any activities of the Other Party occurring at any time during (but not after) the Agreement Term that would be covered by the Other Party’s license under Sections 2.1 or 2.2, as applicable, if such Class B Excluded Special Mask Claim
or Class C Excluded Special Mask Claim, as applicable, were a licensed claim within a Licensed Patent, or (ii) a Covered Entity’s use, import, repair, offer for sale, sale, lease, and other distribution or conveyance at any time before,
during or after the Agreement Term of Licensed Products or Optical Components that were first sold, leased, or otherwise distributed or conveyed by the Other Party at any time before or during (but not after) the Agreement Term and the sale, lease,
or other distribution or conveyance of which by the Other Party or its Subsidiaries would be covered by the Other Party’s or its Subsidiaries’ license under Sections 2.1 or 2.2, as applicable, if such Class B Excluded Special Mask Claim or
Class C Excluded Special Mask Claim were a licensed claim within a Licensed Patent. 
 4.3.3 Limited Covered Entity Immunity. Subject to
Section 4.3.4, the Licensor Party will not Sue any Covered Entity of the Other Party: 
 (a) at any time during or after the Agreement
Term, for direct or indirect infringement (including contributory infringement and inducement to infringe) of any Class A Excluded Special Mask Claim based on such Covered Entity’s use, import, repair, offer for sale, sale, lease, and
other distribution or conveyance at any time before, during or after the Agreement Term of Licensed Products or Optical Components (but, if ASML is such Other Party, only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent
Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product Expansion) that were first sold, leased, or otherwise distributed or conveyed by the Other Party at any time before, during or after the
Agreement Term and the sale, lease, or other distribution or conveyance of which by the Other Party or its Subsidiaries would be covered by the Other Party’s or its Subsidiaries’ license under Sections 2.1 or 2.2, as applicable, if such
Class A Excluded Special Mask Claim were a licensed claim within a Licensed Patent; 
 (b) at any time, during or after the Agreement Term,
for direct or indirect infringement (including contributory infringement and inducement to infringe) of any Class B Excluded Special Mask Claim or Class C Excluded Special Mask Claim based on such Covered Entity’s use, import, repair, offer for
sale, sale, lease, and other distribution or conveyance at any time before, during or after the Agreement Term of Licensed Products or Optical Components (but, if ASML is such Other Party, only as long as ASML has a sublicense from Zeiss SMT under
the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed 

  

					
		  	26	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Product Expansion) that were first sold, leased, or otherwise distributed or conveyed by the Other Party or its Subsidiaries at any time before or during (but not after) the License Term and the
sale, lease, or other distribution or conveyance of which by the Other Party or its Subsidiaries would be covered by the Other Party’s or its Subsidiaries’ license under Sections 2.1 or 2.2, as applicable, if such Class B Excluded Special
Mask Claim or Class C Excluded Special Mask Claim were a licensed claim within a Licensed Patent; and 
 (c) during the Transition Period, for
direct or indirect infringement (including contributory infringement and inducement to infringe) of any Class B Excluded Special Mask Claim or Class C Excluded Special Mask Claim based on such Covered Entity’s use, import, repair, offer for
sale, sale, lease, and other distribution or conveyance at any time prior to the end of the Transition Period of Licensed Products or Optical Components (but, if ASML is such Other Party, only as long as ASML has a sublicense from Zeiss SMT under
the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed Product Expansion) that were first sold, leased, or otherwise distributed or conveyed by the Other Party at any time prior to
or during (but not after) the Transition Period and the sale, lease, or other distribution or conveyance of which by the Other Party or its Subsidiaries would be covered by the Other Party’s or its Subsidiaries’ license under Sections 2.1
or 2.2, as applicable, if such Class B Excluded Special Mask Claim or Class C Excluded Special Mask Claim were a licensed claim within a Licensed Patent. 
 4.3.4 Limitation of Certain Remedies Against Covered Entities as to Transition Period. Nothing in this Agreement (including, without limitation, Section 4.3.3(c) above) shall constitute any
restriction or limitation on the Licensor Party’s right and ability to Sue, after the end of the Transition Period, any Covered Entity of the Other Party for direct or indirect infringement (including contributory infringement and inducement to
infringe) of any Class B Excluded Special Mask Claim or Class C Excluded Special Mask Claim based on such Covered Entity’s use, import, repair, offer for sale, sale, lease, and other distribution or conveyance at any time prior to the end of
the Transition Period of Licensed Products or Optical Components that were first sold, leased, or otherwise distributed or conveyed by the Other Party at any time after the end of the License Term; provided, however, that with respect to Licensed
Products or Optical Components (but, if ASML is such Other Party, only as long as ASML has a sublicense from Zeiss SMT under the Nikon-Zeiss Patent Cross-License Agreement, unless Optical Components are ASML Licensed Products following a Licensed
Product Expansion) that were first sold, leased, or otherwise distributed or conveyed by the Other Party during the Transition Period, the Licensor Party’s remedies in any such action against any Covered Entity of such Other Party shall be
limited to damages in the form of a reasonable royalty not to exceed three percent (3%) of the Net Selling Price of all applicable Licensed Products. 
 4.3.5 Defensive Actions. Notwithstanding anything to the contrary in this Agreement, the immunity described in Section 4.3.3 and the application of Section 4.3.4 are expressly conditioned upon
the applicable Covered Entity not Suing the Licensor Party for Patent infringement, and upon any such Suit such immunity shall retroactively be null and void and of no effect with respect to such Covered Entity, and the Licensor Party shall be
entitled to seek any remedies available against such Covered Entity under applicable Law, including with respect to past activities, but only if the Licensor Party has notified the Other Party of the existence of such Suit and the Covered Entity has
not taken all actions required on its part to withdraw such Suit completely within two (2) months after such notification. No Suit by the Licensor Party against such Covered Entity prior to any such withdrawal shall constitute a breach of this
Section by the Licensor Party as long as the Licensor Party takes all actions required on its part to withdraw such Suit completely within two (2) months after the Covered Entity has taken all actions required on its part to withdraw its Suit
completely. 

  

					
		  	27	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 5.
PAYMENTS 
 5.1 Payments. ASML or ASML Netherlands B.V. (provided that ASML Netherlands B.V. can make such payments only for so long
as it remains a Dutch corporation) shall pay to Nikon the aggregate sum of Eighty-Seven Million U.S. Dollars (US$ 87,000,000), to be payable in the following installments (“PAYMENTS”): 

(a) Sixty Million U.S. Dollars (US$ 60,000,000) on the Effective Date, receipt of which amount on November 16, 2004 is hereby acknowledged by Nikon;

 (b) Nine Million U.S. Dollars (US$ 9,000,000) on the first anniversary of the Effective Date; 

(c) Nine Million U.S. Dollars (US$ 9,000,000) on the second anniversary of the Effective Date; and 

(d) Nine Million U.S. Dollars (US$ 9,000,000) on the third anniversary of the Effective Date. 
 5.2 Taxes. All Payments shall be paid such that, after deduction or withholding of any taxes or other amounts due on such Payments (not including income taxes owed by Nikon) (collectively,
“WITHHOLDINGS”), Nikon receives the entire amounts of such Payments as if no Withholdings had been required. 
 5.3 Late Payments. For
purposes of clarification, ASML shall owe no interest on any Payments set forth in Section 5.1. 
 5.4 Other Payment Provisions. All
amounts payable by ASML to Nikon shall be paid by wire transfer of U.S. Dollars in immediately available funds to the account of “Nikon Corporation,” account number [***], Bank of Tokyo-Mitsubishi Ltd., Head Office, Marunouchi 2-7-1,
Chiyoda-ku, Tokyo, Japan (SWIFT Code BOTKJPJT), or such other financial institution and account number as Nikon may designate in writing to ASML, such notice to be received by ASML no later than two (2) months prior to the applicable date on
which payment is due. Each Party shall be responsible for the proper allocation of payments made under this Agreement in its own tax filings and financial statements. 
 5.5 Audit. The Parties agree to keep full and accurate books and records setting forth in reasonable detail the payments payable to the other Party hereunder, or Glass Product Expenses to be recorded
hereunder, and the calculation thereof. Each Party (the “AUDITING PARTY”) shall have the right to appoint an internationally recognized accounting firm (but not the Auditing Party’s accounting firm) reasonably acceptable to the other
Party (the “INDEPENDENT AUDITOR”) to audit the financial books and records that the other Party (the “AUDITED PARTY”) is expressly required to keep under this Agreement with respect to payments owed to the Auditing Party, or
Glass Product Expenses to be recorded, under this Agreement (the “RELEVANT BOOKS AND RECORDS”). The Audited Party may require the Independent Auditor, prior to any such audit, to agree to reasonable confidentiality restrictions and the
Independent Auditor shall (i) treat as confidential information of the Audited Party all information obtained in connection with such audit and (ii) not disclose the same to the Auditing Party or others, except that the Independent Auditor
may disclose to the Auditing Party only whether the audit revealed an underpayment, or an inaccuracy with respect to Glass Product Expenses, and the amount of such underpayment or inaccuracy, if any. An audit shall be permitted only upon at least
thirty (30) days’ prior written notice to the Audited Party, and in no event more than once during any calendar year (unless an audit in any calendar year revealed an underpayment, in which case the Auditing Party may conduct one
(1) additional audit in such calendar year). The Independent Auditor shall conduct the audit during normal business hours solely as necessary to confirm the accuracy of the Relevant Books and Records. The Independent Auditor may not be paid on
a contingency fee basis and shall provide its report simultaneously to both Parties. The Auditing Party shall be solely liable for all costs and expenses accrued in connection with such audit. In the event the audit reveals an underpayment or
inaccuracy, 

  

					
		  	28	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
prompt adjustment of all unpaid amounts owed under this Agreement shall be made by the Audited Party, provided that nothing contained herein is intended to waive or limit the Audited Party’s
right to contest the accuracy of any finding of the Independent Auditor. 
 6. WARRANTIES AND DISCLAIMERS 

6.1 Authority. Each Party represents and warrants to the other Party that (a) it has all requisite corporate power and authority to execute and
deliver this Agreement and to carry out the provisions of this Agreement, and (b) the execution, delivery and performance by such Party of this Agreement have been approved by all requisite action on the part of such Party, and no other
corporate proceeding on the part of such Party is necessary to authorize this Agreement. 
 6.2 No Conflicts. Each Party represents and warrants
to the other Party that (a) it has the right, and will continue during the Agreement Term to have the right, to grant to the other Party and its Subsidiaries the licenses, rights and immunities granted hereunder in accordance with the terms of
this Agreement, and (b) such grant of licenses, rights and immunities and such Party’s execution, delivery and performance of this Agreement do not, and will not during the Agreement Term, conflict with, violate or result in any breach of
any provision of any license, agreement, contract, understanding, arrangement, commitment or undertaking of any nature (whether written, oral or otherwise) to which such Party is a party. 
 6.3 No Encumbrances With Respect To Owned Licensed Patents. 
 6.3.1 ASML Representations. ASML
hereby represents and warrants to Nikon that, (a) except as set forth in Schedule B-1, no Lithography Patent that is either solely assigned to and/or owned (use of the non-defined term being intentional) by, or Co-Owned by, ASML or its
Subsidiaries as of the Effective Date (but excluding any Excluded Claims thereof) is subject to any lien, encumbrance or other restriction (including any contractual restriction such as an exclusive license) that would prevent or prohibit ASML or
its Subsidiaries from granting to Nikon the full scope of the rights granted under Section 2.2 (excluding rights that employees may have in inventions that they develop while employed by ASML or its Subsidiaries, such as, for example, the right
to receive monetary compensation or assert preemptive rights), and (b) except as set forth in Schedule B-2, since January 1, 1996, neither ASML nor its Subsidiaries have assigned any issued Patents to a third party, except for assignments
that were the result of Patent maintenance decisions in the ordinary course of ASML’s or its Subsidiaries’ business, which Patents would, if Owned by ASML or its Subsidiaries as of the Effective Date, constitute a Lithography Patent
included within the ASML Licensed Patents. 
 6.3.2 Nikon Representations. Nikon hereby represents and warrants to ASML that, (a) except as
set forth in Schedule C-1, no Lithography Patent that is either solely assigned to and/or owned (use of the non-defined term being intentional) by, or Co-Owned by, Nikon or its Subsidiaries as of the Effective Date (but excluding any Excluded Claims
thereof) is subject to any lien, encumbrance or other restriction (including any contractual restriction such as an exclusive license) that would prevent or prohibit Nikon or its Subsidiaries from granting to ASML the full scope of the rights
granted under Section 2.1 (excluding rights that employees may have in inventions that they develop while employed by Nikon or its Subsidiaries, such as, for example, the right to receive monetary compensation or assert preemptive rights), and
(b) except as set forth in Schedule C-2, since January 1, 1996, neither Nikon nor its Subsidiaries have assigned any issued Patents to a third party, except for assignments that were the result of Patent maintenance decisions in the
ordinary course of Nikon’s or its Subsidiaries’ business, which Patents would, if Owned by Nikon or its Subsidiaries as of the Effective Date, constitute a Lithography Patent included within the Nikon Licensed Patents. 

  

					
		  	29	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 6.4 No
Transfers or Encumbrances in Anticipation of Litigation or Execution. Each Party hereby represents to the other, as of the Effective Date, that it has not transferred or assigned any ownership interest in any Patents to any third party, or
encumbered any Patents in a manner that would prevent or prohibit such Party or its Subsidiaries from granting to the other Party and its Subsidiaries the full scope of the rights granted hereunder, in anticipation of Patent litigation with the
other Party or in anticipation of the execution of this Agreement. 
 6.5 Inadvertent Omissions. In the event that a Party discovers after the
Effective Date an inadvertent, good faith omission from its Schedule B or Schedule C, as applicable, such Party shall have the right to update the applicable Schedule hereunder, provided that such omission does not result in any material
disadvantage to the other Party. 
 6.6 No Circumvention. No Circumvention. Each Party agrees that, during the License Term, neither it nor its
Subsidiaries shall initiate any corporate reorganization, merger, spinoff or restructuring that has the foreseeable effect that Lithography Patents having an Effective Application Date after the Effective Date, that would be Licensed Patents of such
Party absent such reorganization, merger, spinoff or restructuring, would be Owned by a Related Company of such Party that is not a Subsidiary of such Party, unless, at the sole election of the first Party, (a) such Related Company is obligated
to grant or extend to the other Party the licenses, immunities, and other commitments that are set forth in this Agreement, or (b) such first Party retains sufficient rights or is granted sufficient sublicensable rights by such Related Company
to grant or extend to the other Party the licenses, immunities, and other commitments that are set forth in this Agreement. For purposes of this Section 6.6, “RELATED COMPANY” means, with respect to any Person, any other Person that
possesses or is under common possession with such first Person, but only for such time as such possession exists. For this purpose, “possession” of a Person (and the correlative “possesses”) means beneficial ownership, directly
or indirectly, of securities representing more than fifty percent (50%) of the power to elect such other Person’s board of directors or other managing authority or, in the case of non-corporate Person, equivalent interests. 

6.7 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS), WITH RESPECT TO THIS
AGREEMENT, ANY REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, AND ANY WARRANTIES THAT MAY ARISE FROM COURSE OF
PERFORMANCE, COURSE OF DEALING OR USAGE OF TRADE. 
 7. LIMITATION OF LIABILITY 

TO THE EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER ANY LEGAL THEORY FOR ANY INDIRECT, SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, OR ANY DAMAGES FOR LOSS OF PROFITS, REVENUE OR BUSINESS, ARISING OUT OF ANY BREACH OF THIS AGREEMENT BY SUCH PARTY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR FOR ANY
FINES, PENALTIES, OR LEVIES ASSESSED AGAINST THE OTHER PARTY BY ANY GOVERNMENTAL AUTHORITY. 
 8. TERM AND TERMINATION 

8.1 Term of Agreement. This Agreement will be effective as of the Effective Date, and except as expressly set forth in Section 8.2, will continue in
full force and effect until the end of the 

  

					
		  	30	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
Agreement Term, after which it will expire, subject to Sections 8.2.1 and 8.5. Except as expressly set forth in Section 8.2, neither Party shall have the right, during the Agreement Term, to
terminate this Agreement, any of its obligations hereunder, or any of the rights, licenses, immunities, or additional commitments granted or extended by such Party hereunder. 
 8.2 Expiration/Termination of Licenses. 
 8.2.1 Expiration of License Term. Except as otherwise
set forth in Sections 2.8.4 and 8.2.2 of this Agreement, and notwithstanding any breach of this Agreement other than non-payment and failure to cure such non-payment as set forth in Section 8.2.2, (a) the licenses and rights granted in
Sections 2.1 and 2.2 to each Party and its Subsidiaries under the other Party’s Class B Patents shall terminate on the expiration of the License Term, (b) the rights and licenses granted in Sections 2.1 and 2.2 to each Party and its
Subsidiaries under each of the other Party’s Class A Patents shall continue until the expiration of such Class A Patent, notwithstanding the expiration of the License Term or Agreement Term, and (c) the immunities and additional
commitments under Sections 2.7, 2.9, 3 and 4 shall continue as provided in those Sections, respectively. 
 8.2.2 Non-Payment By Zeiss SMT or
ASML. If ASML fails to pay to Nikon any of the payment installments set forth in Section 5.1 on the due dates thereof or if Zeiss SMT fails to pay to Nikon any of the outstanding payments described in Section 5.1 of the Nikon-Zeiss Patent
Cross-License Agreement (in the form in which such agreement exists as of the Effective Date) by the due dates thereof (the “ZEISS SMT PAYMENTS”), then Nikon shall provide written notice of such non-payment to both ASML and Zeiss SMT. If
neither ASML nor Zeiss SMT pays all delinquent amounts identified in such notice to Nikon within thirty (30) days after Nikon’s written notice of such non-payment, then Nikon shall have the right to terminate the rights, licenses,
immunities, and additional commitments granted to ASML and its Subsidiaries and their respective Covered Entities, vendors and Glass Suppliers in Sections 2, 3, and 4. For purposes of clarification, no termination of such rights, licenses,
immunities, and additional commitments shall terminate or otherwise affect the rights, licenses, immunities, and additional commitments granted to Nikon and its Subsidiaries, and their respective Covered Entities, vendors, and Glass Suppliers in
Sections 2, 3, and 4. Notwithstanding anything to the contrary in this Section 8.2.2, once all payments set forth in Section 5.1 and all Zeiss SMT Payments have been paid to Nikon in full (regardless of whether such payments are made by
Zeiss SMT or ASML), Nikon shall have no right to terminate the rights, licenses and immunities granted by Nikon and its Subsidiaries to ASML and its Subsidiaries hereunder. 
 8.3 Change of Control of Subsidiaries. If a Subsidiary of a Party ceases to be a Subsidiary of such Party (“CHANGE OF STATUS”), (a) the licenses, rights, immunities, and additional
commitments granted to such Subsidiary and Covered Entities, vendors, or Glass Suppliers of such Subsidiaries under Sections 2, 3, and 4 shall immediately terminate upon the consummation of such Change of Status, without limiting the immunity, as
provided in Sections 2.7, 3.1, 3.2, 3.3, and 4.3, as applicable, of the relevant Covered Entities to which such Covered Entities were entitled as of the date of such termination, and (b) the licenses, rights and immunities granted in this
Agreement under the Licensed Patents of such Subsidiaries will remain in effect, in accordance with the terms and conditions of this Agreement, with respect to such of those Licensed Patents that have an Effective Application Date prior to the
consummation of such Change of Status, but not with regard to any Patents that have an Effective Application Date after the consummation of such Change of Status. 
 8.4 Continuing Liability. The expiration of this Agreement shall not release either Party from any liability, obligation or agreement which has already accrued under this Agreement at the time of such
expiration. The expiration of this Agreement shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, which a Party may have hereunder, at
law or otherwise. 

  

					
		  	31	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 8.5 Survival.
The provisions of Sections 1, 2.1 (only with respect to Class A Patents that are Licensed Patents as provided in Section 8.2.1), 2.2 (only with respect to Class A Patents that are Licensed Patents as provided in Section 8.2.1),
2.4 (only with respect to Class A Patents), 2.5 (for the periods set forth therein), 2.6, 2.7 (as set forth therein), 2.8, 2.9.2, 2.9.3, 3.1 (only as set forth therein), 3.2 (only as set forth therein), 3.3 (only as set forth therein), 4.1, 4.2
(only as set forth therein), 4.3 (only as set forth therein), 5 (as applicable), 6.7, 7, 8.2, 8.3, 8.4, 8.5, 9, and 10, and any other sections of this Agreement to the extent expressly provided herein, shall survive, to the extent applicable, the
expiration of this Agreement. 
 9. ASSIGNMENT 
 9.1 Sale of Lithography Business. Either Party may assign this Agreement, together with all of its rights and obligations hereunder as well as all of the rights sublicensed to ASML and its Subsidiaries
(and the other benefits extended) pursuant to Section 2.2 of the Nikon-Zeiss Patent Cross-License Agreement, to any Person that acquires all of such Party’s rights in the Lithography Patents included within the Licensed Patents of such
Party and all or substantially all of the other assets of the business of manufacturing and selling Licensed Products of the assigning Party or its Subsidiary, as applicable, provided, however, that the assigning Party shall remain liable for the
performance of all of its obligations under this Agreement. 
 9.2 No Other Assignment. Except as permitted under Section 9.1, neither
Party may assign, delegate, or otherwise transfer any of its rights or obligations under this Agreement to any other Person without the prior written consent of the other Party. Any purported or attempted assignment, delegation or other transfer of
any rights or obligations under this Agreement in contravention of the foregoing sentence shall be null and void. 
 9.3 Transfer of Patents. In
the event of any sale, assignment, transfer, exclusive license, or other conveyance of any ownership interest in a Party’s Licensed Patents (“TRANSFER”), such Party shall (i) ensure that the purchaser, assignee, transferee, or
exclusive licensee (“TRANSFEREE”) shall be bound by all applicable licenses, immunities, covenants, and restrictions contained in this Agreement, (ii) require that such Transferee agree in writing prior to any such Transfer to be
bound by all licenses, immunities, covenants, and other restrictions hereunder, and (iii) ensure that such Transfer does not affect such Party’s right and ability to perform all of its obligations under this Agreement. In no event shall
such Party be relieved or excused from any of its obligations under this Agreement as a result of such Transfer. Notwithstanding anything to the contrary contained in Section 10.12, each Party shall have the right to file this Agreement, and
ASML shall have the right to file any sublicense agreement with Zeiss SMT (including, to the extent attached thereto, the Nikon-Zeiss SMT Patent Cross-License Agreement) or any summary or translation hereof or thereof with any patent office or other
Governmental Authority in order to notify potential Transferees of the existence and terms of this Agreement or such sublicense as it relates to any Licensed Patents proposed to be Transferred, provided that prior to any such filing the other Party
shall be given an opportunity to propose reasonable redactions to be made to the filed version of this Agreement or such sublicense and the Parties shall cooperate with respect to agreeing on such redactions. Each Party shall provide all reasonable
cooperation requested by the filing Party, at the filing Party’s expense, including, without limitation, the execution, delivery and filing of any applicable instruments, notifications, forms, affidavits and the like. 

  

					
		  	32	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 9.4 Successors
and Assigns. Subject to the other provisions of this Section 9, this Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. 

10. MISCELLANEOUS 
 10.1 Limitation.
Nothing contained in this Agreement shall be construed as: 
 10.1.1 a warranty or representation by either Party as to the validity,
enforceability or scope of any Patents; or 
 10.1.2 conferring upon any Person any license, right or immunities under any Patents except the
licenses, rights and immunities expressly granted hereunder; or 
 10.1.3 a warranty or representation that any acts licensed hereunder will be
free from infringement or other violation of Patents, copyrights, mask work rights, trade secrets or other intellectual property rights, other than infringement of those Licensed Patents under which licenses, rights and immunities have been
expressly granted hereunder; or 
 10.1.4 an obligation of either Party or its Subsidiaries to file or maintain any patent application, secure
any Patent or maintain any Patent in force; or 
 10.1.5 an arrangement to Sue third parties for infringement of any Patent or other
intellectual property right or conferring any right to Sue third parties for infringement of any Patent or other intellectual property right. 

10.2 Relationship of the Parties. In the exercise of their respective rights, and the performance of their respective obligations hereunder, the Parties
are and will remain independent contractors. Nothing in this Agreement will be construed to constitute the Parties as partners, or principal and agent for any purpose whatsoever. Neither Party will bind, or attempt to bind, the other Party to any
contract or other obligation, and neither Party will represent to any third party that it is authorized to act on behalf of the other Party. 

10.3 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York, United States of America
(without application of any choice or conflicts of laws rules or principles that would require the application of the laws of any other jurisdiction). 
 10.4 Dispute Resolution. The Parties hereby agree that any controversy, claim or dispute arising out of or relating to this Agreement or the breach hereof shall be resolved in accordance with the terms
and conditions of the Arbitration Agreement. Except as permitted under the Arbitration Agreement, the Parties hereby give up and waive any rights they might have to have such disputes decided in a court or jury trial. 

10.5 Language. This Agreement is in the English language only, which language shall be controlling in all respects, and all versions hereof in any other
language shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement shall be in the English language. 

10.6 Entire Agreement; Amendment; Waiver. This Agreement (including the Schedules hereto), the Arbitration Agreement, the Patent Cooperation Agreement
between Nikon and 

  

					
		  	33	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
ASML of even date herewith, and the Nikon-ASML Settlement and Release Agreement (together the “TRANSACTION AGREEMENTS”) constitute the full and entire understanding and agreement
between Nikon and ASML with regard to the subject matter hereof, and supersede any communications, representations, understandings and agreements (including the MOU), either oral or written, between Nikon and ASML prior to, but not on, the date
hereof, with respect to such subject matter. This Agreement may not be altered or amended except by a written instrument signed by authorized legal representatives of both Parties. Any waiver of the provisions of this Agreement or of a Party’s
rights or remedies under this Agreement must be in writing to be effective. Failure, neglect or delay by a Party to enforce the provisions of this Agreement or its rights or remedies at any time will not be construed and will not be deemed to be a
waiver of such Party’s rights under this Agreement and will not in any way affect the validity of the whole or any part of this Agreement or prejudice such Party’s right to take subsequent action. No single or partial exercise of any
right, power or privilege granted under this Agreement shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. Except as expressly set forth in this Agreement, the rights and remedies provided in
this Agreement are cumulative and are not exclusive of any rights or remedies provided by law or in any other agreement between the Parties. 

10.7 Notices and Other Communications. All notices required or permitted under this Agreement shall refer to this Agreement and will be deemed given:
(a) when delivered personally; (b) when sent by confirmed facsimile; or (c) three (3) business days after deposit with an internationally recognized commercial overnight carrier specifying next-day delivery, with written
verification of receipt. All such notices, requests, demands and other communications shall be addressed as follows: 
 If to Nikon: 

Nikon Corporation 
 6-3, Nishi-ohi 1-chome

 Shinagawa-ku 
 Tokyo 140-8601

 Japan 
 Attn: General Manager,
Intellectual Property Department 
 Fax: +81-3-3778-2900 
 With a copy to (which shall not constitute notice): 
 Morrison & Foerster LLP 

425 Market Street 
 San Francisco, CA 94105

 Attn: Robert Townsend 
 Fax: +1
(415) 268-7522 
 If to ASML: 

ASML Holding N.V. 
 De Run 6501 

5504 DR Veldhoven 
 The Netherlands 

Attn: General Counsel 
 Fax: +31
(40) 268-2000 
 With a copy to (which shall not constitute notice): 
 Wilmer Cutler Pickering Hale and Dorr LLP 
 60 State Street 

Boston, MA 02109 
 Attn: William F. Lee

 Fax: +1 (617) 526-5000 

  

					
		  	34	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 or to such
other address or facsimile number as a Party may have specified to the other Party in writing delivered in accordance with this Section 10.7. 10.8 Expenses. Except as otherwise expressly set forth in this Agreement, each Party will bear its own
costs and expenses, including fees and expenses of legal counsel and other representatives used or hired in connection with the transactions described in this Agreement. 
 10.8 Severability. If any provision in this Agreement is found or held to be invalid or unenforceable, then the meaning of such provision will be construed, to the extent feasible, so as to render the
provision enforceable and still achieve the Parties’ intent in entering into this Agreement, and if no feasible interpretation would save such provision, it will be severed from the remainder of this Agreement, which will remain in full force
and effect. In such event, the Parties and Zeiss SMT will use all reasonable efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement which most nearly effects the Parties’ intent in entering into this
Agreement. 
 10.9 Construction. This Agreement shall be deemed to have been drafted by both Parties and, in the event of a dispute, neither
Party shall be entitled to claim that any provision should be construed against the other Party by reason of the fact that it was drafted by the other Party. 
 10.10 Execution. This Agreement may be executed in counterparts, each of which so executed will be deemed to be an original and such counterparts together will constitute one and the same agreement.
Execution and delivery of this Agreement by exchange of facsimile copies bearing the facsimile signature of a Party shall constitute a valid and binding execution and delivery of this Agreement by such Party. 

10.11 Confidentiality of Terms. Neither Party shall (and shall ensure that none of its agents, representatives or attorneys shall) disclose the terms of
this Agreement to any third parties, except that either Party may disclose the existence of this Agreement to third parties, and may disclose the terms of this Agreement (a) to the extent reasonably necessary, in confidence, to its legal
counsel and accountants, (b) to Governmental Authorities as required by any applicable Law or the applicable rules or regulations of any securities exchange on which any of such Party’s securities are listed (in either case, as determined
by such Party upon advice of counsel), provided that prior to any such required disclosure, the disclosing Party gives the non-disclosing Party reasonable advance notice of such disclosure, minimizes the scope of such disclosure (including by making
redactions to documents provided as part of such disclosure and by cooperating with the non-disclosing Party to obtain protective orders) to the extent permitted under applicable Law, and otherwise coordinates with the non-disclosing Party with
respect to the scope of such disclosure, (c) in connection with the enforcement of this Agreement or any other Transaction Agreement, or (d) as permitted under Section 9.3. Notwithstanding the foregoing, neither Party will be
prohibited from disclosing, in their entirety, the terms of any of Sections 2.8, 3.1, 3.2, 3.3, 4.2 or 4.3, and the obligations of the Parties under this Section 10.12 shall not apply to any terms of this Agreement that have been disclosed by
either Party as permitted by subclauses (a)-(d) above. 
 10.12 Publicity. No Party shall (and shall ensure that none of its agents,
representatives or attorneys shall) originate any publicity, news release, or other public announcement, written or oral, relating to this Agreement without the prior written approval of each other Party except as otherwise required by Law. Such
approval shall not be unreasonably withheld. Notwithstanding the foregoing, nothing in this Section 10.13 shall prevent or prohibit, or be construed to require approval by any Party for, (a) any disclosure of information or matters
relating to this Agreement to a Party’s customers, resellers, or suppliers in the ordinary course of business where, with respect to information that constitutes confidential information of another Party under one or more of the Transaction
Agreements, 

  

					
		  	35	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 
such disclosure is subject to the terms of a non-disclosure agreement in customary form, or (b) any publicity, news release or other public announcement of information that (i) is or
becomes available to the general public other than in violation of Section 10.12 or obligations of confidentiality under any other Transaction Agreement, or (ii) otherwise does not constitute confidential information of another Party under
the Transaction Agreements. 
 10.13 Section 365(n). Each Party, as licensor, acknowledges and agrees that the licenses, immunities and
rights granted under this Agreement to the other Party and its Subsidiaries by such licensor are licenses, immunities and rights as to “intellectual property” within the definition of Section 101(35A) of the United States Bankruptcy
Code (the “CODE”). The Parties hereto further agree that, in the event of the commencement of a bankruptcy proceeding by or against the licensor Party under the Code, the licensee Party and its Subsidiaries shall be entitled, at such
licensee Party’s option, to retain all their licenses, immunities and rights under this Agreement, including without limitation the licenses and immunities granted under Sections 2.1 and 2.2, respectively, pursuant to Code Section 365(n).
To the extent that United States law is held by a court of competent jurisdiction not to apply with respect to a non-US bankruptcy proceeding of a Party, each Party shall take all actions that are reasonably necessary to effectuate the intent of the
foregoing provisions in the country in which it and each Subsidiary holding any rights with respect to its Licensed Patents is incorporated or conducts its business, subject to any mandatory provisions of applicable law. Without limiting the
generality of the foregoing, Nikon agrees to take all reasonable measures necessary to ensure the survival of the rights, immunities, and licenses granted to ASML and its Subsidiaries in the event that Nikon or any of its Subsidiaries is subject to
a bankruptcy proceeding under the laws of Japan, and ASML agrees to take all reasonable measures necessary to ensure the survival of the rights, immunities, and licenses granted to Nikon and its Subsidiaries in the event that ASML or any of its
Subsidiaries is subject to a bankruptcy proceeding under the laws of the Netherlands, in each case in accordance with applicable law. 
 10.14
Nikon-Zeiss Patent Cross-License Agreement. Nikon agrees that it shall not, without the prior written consent of ASML, agree or consent to any amendment, modification, or termination of the Nikon-Zeiss Patent Cross License Agreement that limits in
scope or duration Zeiss SMT’s rights to grant sublicenses to ASML and its Subsidiaries (and to extend to ASML, its Subsidiaries and their respective Covered Entities benefits of immunities, covenants not to sue, and additional commitments)
under Section 2.2 of the Nikon-Zeiss Patent Cross License Agreement as of the Effective Date hereof. 
 10.15 Further Assurances. Each
Party agrees (a) to furnish upon request to the other Party such further information, (b) to execute and deliver to the other Party such other documents, and (c) to do such other acts and things, in each case as the Party may
reasonably request for the purpose of carrying out the purposes, terms and conditions of this Agreement. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK.] 

  

					
		  	36	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 IN WITNESS
WHEREOF, the Parties have caused this Agreement to be executed and delivered by their respective duly authorized representatives as of the date first above written. 
  

									
	NIKON CORPORATION	 		 	ASML HOLDING N.V.
					
	By:	 	/s/ Kenzi Enya	 		 	By:	 	/s/ Ton van Hoef
	Name:	 	Kenzi Enya	 		 	Name:	 	Ton van Hoef
	Title:	 	Vice Chairman and Chief Financial Officer	 		 	Title:	 	VP and Chief IP Counsel

  

					
		  	37	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 SCHEDULE A

 EXCLUDED CLAIMS LIST 
 To
be added pursuant to Section 2.3.1. 

  

					
		  	38	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
  
 SCHEDULE
B-1 
 ASML DISCLOSURES PURSUANT TO SECTION 6.3.1(a) 
 None. 

  

					
		  	39	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE B-2 
 ASML DISCLOSURES PURSUANT TO SECTION 6.3.1(b) 
  

																	
	COUNTRY NAME	  	FILING NR	 	  	FILING DATE	 	  	PATENT NR	 	  	ASSIGNEE	 
					
	European (E.P.O.)	  				  	 	12/19/2001	  	  	 	1 217 450	  	  	 	Carl Zeiss Stiftung	  
	GermanyDE	  	 	10061480.9	  	  	 	12/8/2000	  	  				  	 	Carl Zeiss Stiftung	  
	Germany	  	 	10144246.7	  	  	 	9/5/2001	  	  	 	 	 	  	 	Carl Zeiss Stiftung	  

  

					
		  	40	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE C-1 
 NIKON DISCLOSURES PURSUANT TO SECTION 6.3.2(a) 
 All Patents that are based on the same
priority document as the Patents listed in the following table shall be deemed part of Schedule C-1 without being expressly listed in the following table. 
  

													
	 COUNTRY

NAME
	  	APPLICATION
NUMBER	  	 DATE OF

FILING
	  	LAID OPEN
NUMBER	  	 DATE LAID

OPEN
	  	 PATENT

NUMBER
	  	COUNTERPART
PATENTS
							
	[***]	  	 	  	 	  	 	  	 	  	 	  	 

  

					
		  	41	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE C-2 
 NIKON DISCLOSURES PURSUANT TO SECTION 6.3.2(b) 
 [***] 

  

					
		  	42	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE D 
 SCHEDULE D PATENTS 
 The three Patent applications having international publication numbers:

 [***] 
 [***] 

[***] 

  

					
		  	43	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE E 
 DESIGNATED NIKON PATENTS 
 The three Patent applications having international publication
numbers: 
 [***] 
 [***] 

[***] 

  

					
		  	44	  	

 *** - indicates material omitted pursuant to a confidential treatment request and filed separately with the
Securities and Exchange Commission. 
 SCHEDULE F 
 SPECIFIED ENTITY 
 [***], a corporation organized under the laws of [***]. 

  

					
		  	45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]